



# Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Bing Li, Li Liang, Huijie Deng, Jinmin Guo, He Shu and Li Zhang\*

Department of Pharmacy, 960th Hospital of the PLA, Jinan, China

**Background:** Irritable bowel syndrome is a functional gastrointestinal disease. Evidence has suggested that probiotics may benefit IBS symptoms. However, clinical trials remain conflicting.

**Aims:** To implement a systematic review and meta-analysis of clinical trials regarding the efficacy and safety of probiotics for IBS patients.

#### **OPEN ACCESS**

#### Edited by:

Tahir Mehmood Khan, University of Veterinary and Animal Sciences, Pakistan

#### Reviewed by:

Inayat Rehman, Monash University Malaysia, Malaysia Sunita Nair, Consultant, Mumbai, India

> \***Correspondence:** Li Zhang jjzyyzl1210@163.com

#### Specialty section:

This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology

Received: 06 November 2019 Accepted: 06 March 2020 Published: 03 April 2020

#### Citation:

Li B, Liang L, Deng H, Guo J, Shu H and Zhang L (2020) Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Front. Pharmacol. 11:332. doi: 10.3389/fphar.2020.00332 **Methods:** We searched for relevant trials in Medline(1966 to Jan 2019), Embase(1974 to Jan 2019), the Cochrane Central Register of Controlled Trials(up to Jan 2019), the ClinicalTrials.gov trials register(up to Jan 2019), and Chinese Biomedical Literature Database(1978 to Jan 2019). Risk ratio (RR) and a 95% confidence interval (CI) were calculated for dichotomous outcomes. Standardized mean difference (SMD) and 95% CI were calculated for continuous outcomes.

# **Results:** A total of 59 studies, including 6,761 patients, were obtained. The RR of the improvement or response with probiotics versus placebo was 1.52 (95% Cl 1.32–1.76), with significant heterogeneity ( $I^2 = 71\%$ , P < 0.001). The SMD of Probiotics in improving global IBS symptoms vs. Placebo was -1.8(95% Cl -0.30 to -0.06), with significant heterogeneity ( $I^2 = 65\%$ , P < 0.001). It was impossible to draw a determinate conclusion. However, there were differences in subgroup analyses of probiotics type, dose, treatment duration, and geographic position. Probiotics seem to be safe by the analysis of adverse events(RR = 1.07; 95% Cl 0.92–1.24; $I^2 = 0$ , P = 0.83).

**Conclusion:** Probiotics are effective and safe for IBS patients. Single probiotics with a higher dose (daily dose of probiotics  $\geq 10^{10}$ ) and shorter duration (< 8 weeks) seem to be a better choice, but it still needs more trials to prove it.

Keywords: efficacy, safety, irratable bowel syndrome, probiotics, meta-analysis

# INTRODUCTION

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with abdominal pain, bloating and altered bowel habits (Drossman et al., 2002). It affects 11% of the world-wide population (Lovell and Ford, 2012). IBS reduces health-related quality of life (HRQOL) (Gralnek et al., 2000; Wang et al., 2012) and leads to a significant economic healthcare burden.

1

Although the exact etiology and pathogenesis underlying IBS are still incompletely understood, studies show that IBS was associated with the gastrointestinal (GI) microbiota, chronic low-grade mucosal inflammation, altered regulation of the gutbrain axis, immune function, visceral hypersensitivity, and psychosocial factors(Parkes et al., 2008; Dupont, 2014; Hayes et al., 2014). Since there is no effective cure for IBS, the treatment focuses on alleviating the particular symptoms. New therapeutic options for IBS include tricyclic antidepressants (Rahimi et al., 2009), spasmolytics (Tack et al., 2016), selective serotonin reuptake inhibitors (Bundeff and Woodis, 2014), lubiprostone (Chang et al., 2016) and linaclotide (Chey et al., 2011), and 5hydroxytryptamine type-3 antagonists such as ramosetron and alosetron (Andresen et al., 2008). However, current treatments are not very useful or may cause adverse reactions (Trinkley and Nahata, 2014).

Evidence (Durban et al., 2013; Jalanka-Tuovinen et al., 2014) has suggested that intestinal microorganisms play an important role in IBS, as numerous studies have indicated that an irregular composition or metabolic activity of intestinal flora in patients with IBS (Simrén et al., 2013; Spiller et al., 2016; Thijssen et al., 2016; Hod et al., 2017; Shin et al., 2018). Therefore, the regulation of the gut microbiota by probiotics is a promising treatment for IBS (Hyland et al., 2014). Probiotics can improve intestinal flora and limit colonization of pathogenic bacteria (Guarner et al., 2012). Investigators have performed numerous clinical trials to assess the efficacy of probiotics for IBS. However, the conclusions have been controversial. Some trials have suggested that probiotics can improve global IBS symptoms (Lyra et al., 2016). Others have demonstrated no effect (Charbonneau et al., 2013). Several articles have not found an apparent effect of probiotics on global IBS symptoms, but have found improvement of individual IBS symptoms (Sisson et al., 2014). Therefore, we conducted this meta-analysis to examine the efficacy of global IBS symptoms improvement, global symptoms scores, and individual symptom scores, such as abdominal pain and bloating. Additionally, this study evaluated the safety of probiotics.

# METHODS

## Search Strategy and Selection Criteria

We included all eligible randomized placebo-controlled, trials (RCTs) of probiotics treatment in adult IBS. We searched Medline(1966 to Jan 2019), Embase(1974 to Jan 2019), the Cochrane Central Register of Controlled Trials(up to Jan 2019), the ClinicalTrials.gov trials register(up to Jan 2019), and Chinese Biomedical Literature Database(CBM) (1978 to Jan 2019) for relevant trials. We used the terms "probiotics" and "irritable bowel syndrome" both as medical subject heading (Mesh) and free text terms. The exact search strategy in Medline was ("probiotics"[MeSH Terms] OR "probiotics"[Title/Abstract]) AND ("irritable bowel syndrome"[MeSH Terms] OR "irritable bowel syndrome"[Title/Abstract]) AND ("randomized controlled trial" [pt] OR "randomized controlled trial" [tiab]).

We used the following eligibility criteria: (1) the studies were randomized controlled trials (RCTs) comparing probiotics with placebo; (2) diagnostic criteria included but were not limited to the Manning criteria, and Rome I, Rome II, or Rome III criteria. We did not exclude trials in which patients were stated to be diagnosed with IBS but no diagnostic criteria were described; (3) the age of participants were  $\geq 18$  years; (4) minimum treatment duration was 7 days. Studies were excluded if they met: (1) studies with inadequate information; (2) probiotics along with other drugs; (3) control group was not placebo; (4) data were not available after contacting the authors. There were no language limitation. Articles in foreign language were translated as needed.

# **Outcome Assessment**

The primary outcomes were the efficacy of probiotics on global IBS symptoms improvement or response to therapy. Secondary outcomes involved the effect on global symptoms scores and individual symptom scores, such as abdominal pain and bloating. The safety of probiotics was also evaluated.

# **Data Extraction**

Two reviewers extracted data from included trials independently. All data was inspected by a third reviewer. Any divergence was solved by consensus. Following data were extracted:author publication year, country, type of IBS(%), diagnostic criteria for IBS, recruitment, sample size, number of male/female, age, probiotic, dosage, duration of therapy, criteria to define symptom improvement or response, and outcomes.

# Assessment of Risk of Bias

Two reviewers performed the assessment of study quality independently. Disagreements were solved by discussion. The risk of bias were evaluated according to the Cochrane handbook (Higgins and Green, 2011). Random sequence generation and allocation concealment(selection bias), blinding of participants and personnel(performance bias), blinding of outcome assessment(detection bias), incomplete outcome data(attrition bias), selective reporting(reporting bias), and other biases were assessed.

# **Statistical Analyses**

Random effects model was used (Dersimonian and Laird, 1986) to get a conservative estimation for the effect. As dichotomous outcomes, the efficacy on global IBS symptoms improvement or overall symptom response and the safety of probiotics were evaluated by RR(risk ratio) and 95% CIs(confidence intervals). As continuous outcomes, global symptoms scores, and individual symptoms scores were assessed using standardised mean difference (SMD) and corresponding 95% CIs. A negative SMD was defined to indicate beneficial effects of probiotics compared with placebo for outcomes. Subgroup analyses based on probiotic type, dosage, and treatment duration were conducted.

Heterogeneity was tested by I<sup>2</sup> statistic and the Cochran Q-test. I<sup>2</sup>  $\geq$  50 and P < 0.10 were considered as a significant heterogeneity (Higgins et al., 2003). When there was significant heterogeneity, sensitivity analyses were conducted to give possible explanation. Review Manager version 5.3.5 (the

Nordic Cochrane Center, Copenhagen, Denmark) was used to obtain forest plots of RRs and SMDs Egger test (Egger et al., 1997) (P < 0.10 defined existence of possible publication bias) and funnel plots was calculated by Stata Statistical Software: Release 13 (StataCorp LP; College Station, TX).

# RESULT

Based on network searching, a total of 4,830 citations were retrieved. By removing duplicates and screening titles and abstracts, 220 studies remained to be relevant (**Figure 1**). Excluding 161 studies for diverse reasons, 59 studies (Gade and Thorn, 1989; Nobaek et al., 2000; Niedzielin et al., 2001; Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; Niv et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Simren and Lindh, 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Enck et al., 2008; Kajander et al., 2009; Sinn et al., 2008; Zeng et al., 2008; Agrawal et al., 2009; Enck et al., 2009; Hong et al., 2009; Williams et al., 2009; Simrén et al., 2011; Choi et al., 2011; Guglielmetti et al., 2011; Michail and Kenche, 2011; Sondergaard et al., 2011; Cha et al., 2012; Cui and Hu, 2012; Dapoigny et al., 2012; Ducrotte et al., 2012; Farup et al., 2012; Kruis et al., 2012; Amirimani et al., 2013; Begtrup et al., 2013; Charbonneau et al., 2013; Roberts et al., 2013; Abbas et al., 2014; Jafari et al., 2014; Lorenzo-Zuniga et al., 2014; Ludidi et al., 2014; Pedersen et al., 2014; Shavakhi et al., 2014; Sisson et al., 2014; Stevenson et al., 2014; Yoon et al., 2014; Faghihi et al., 2015; Pineton de Chambrun et al., 2015; Yoon et al., 2015; Lyra et al., 2016; Majeed et al., 2016; Mezzasalma et al., 2016; Spiller et al., 2016; Thijssen et al., 2016; Hod et al., 2017; Ishaque et al., 2018; Khodadoostan et al., 2018; Kim et al., 2018; Preston et al., 2018; Sun et al., 2018), which contained 6,721 participants, were eligible evaluating. The agreement between the two researchers was well established (kappa value = 0.91). The characteristics of the included RCTs are presented in Table 1. The risk of bias was shown in Figure 2 and Figure 3. Twenty-three studies did not describe the details of the sequence generation process (Nobaek et al., 2000; Niedzielin et al., 2001; Niv et al., 2005; Simren and Lindh, 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Enck et al., 2008; Zeng et al., 2008; Agrawal et al., 2009; Enck et al., 2009; Williams et al., 2009; Cui




TABLE 1   Characteristics of randomized controlled trials of probiotics versus placebo in irritable bo	owel syndrome.
--	----------------

Study	Year	Country	Type of IBS (%)	diagnostic criteria for	recruitment	Sample size	Sex (Male	/Female)	Age [years],	Probiotic	Probiotic dosage (CFU/D)	Duration of	Criteria used to define symptom improvement	Outcome
			(%)	IBS		size	Probiotic	Placebo	[years], mean ± SD		(CF0/D)	therapy	following therapy or response	
Gade and Thorn (1989)	1989	Denmark	all types	Manning	Primary care	54	5/27	7/15	34	Streptococcus faecium	Not stated	4 weeks	IBS symptoms "improved"	Improvement in IBS symptoms Adverse events
Nobaek et al. (2006)	2000	Sweden	all types	Rome I	Advertisement	52	9/16	7/20	51	Lactobacillus plantarum	5×10 <sup>7</sup>	4 weeks	<ul> <li>&gt; 1.5 improvement in VAS scale for abdominal pain, and continuous scale for IBS symptoms</li> </ul>	Abdominal pain(VAS)
Niedzielin et al. (2001)	2001	Poland	all types	clinical diagnosis	Primary care	40	5/15	3/17	45	Lactobacillus plantarum	2×10 <sup>10</sup>	4 weeks	improvement in IBS symptoms	Improvement in IBS symptoms Adverse events
Kim et al. (2003)	2003	USA	D:100	Rome II	Secondary care	25	2/10	5/8	42.8 ± 16.7	Combination	9×10 <sup>11</sup>	8 weeks	Satisfactory relief of IBS symptoms for 50% of weeks, and continuous scale for IBS symptoms	Response(Satisfactory relief of IBS symptoms for 50% of weeks) Overall symptoms scor Bloating(100-mm VAS Abdominal pain(100- mm VAS) Adverse events
Kajander et al. (2005)	2005	Finland	D:48 C:23 A:29	Rome I and II	Advertising	103	13/39	11/40	46	Combination	8–9×10 <sup>9</sup>	6 months	Relief of IBS symptoms, and continuous scale for IBS symptoms	Global symptoms scor Abdominal pain(a 4- point numerical scale) Adverse events
Kim et al. (2005)	2005	USA	D:42 C:33 A:25	Rome II	Secondary care and advertising	48	3/21	0/24	43	Combination	9×10 <sup>11</sup>	4-8 weeks	Satisfactory relief of IBS symptom for 50% of weeks	Response(Satisfactor relief of IBS symptom for 50% of weeks) Bloating(100-mmVAS Abdominal pain(100- mmVAS) Adverse events
Niv et al. (2005)	2005	Israel	D:37 C:18.5 M:44.4	Rome II	Secondary care	54	7/20	11/16	45.6	L. reuteri ATCC 55730	4×10 <sup>8</sup> for 1wk, then 2×10 <sup>8</sup>	6 months	continuous scale for IBS symptoms	Global symptoms scor Adverse events
O'Mahony et al. (2005)	2005	Ireland	D:28 C:26 A:45	Rome II	Secondary care	75	not si	tated	44.3	L. salivarius UCC4331 or B. infantis 35624	1×10 <sup>10</sup>	8 weeks	Continuous scale for IBS symptoms	Global symptoms scor Abdominal pain(7-poir Likert score) Bloating(7-pointLikert score) Adverse events
Kim et al. (2006)	2006	Korea	D:70 A:30	clinical diagnosis	Secondary care	34	14/3	11/6	39.35 ± 11.9	Combination	3×10 <sup>9</sup> (Bacillus subtilis) 2.7×10 <sup>10</sup> (Streptococcus faecium)	4 weeks	Continuous scale for IBS symptoms	Bloating(10-pointVAS) Abdominal pain(10- pointVAS) Adverse events
Simren and Lindh (2006)	2006	Sweden	all types	Rome II	Advertising	76	not s	tated	40	L.plantarum DSM 9843	2×10 <sup>10</sup>	6 weeks	Continuous scale for IBS symptoms	Global symptoms sco (IBS-SSS)
Whorwell et al. (2006)	2006	UK	D:55.5 C:20.7 A:23.8	Rome II	Primary care	362	0/270	0/92	41.9 ± 10.46	B. infantis 35624	1×10 <sup>6</sup> ,1×10 <sup>8</sup> ,1×10 <sup>10</sup>	4 weeks	Subjects' Global Assessment (SGA) of IBS symptoms,and continuous scale symptoms for IBS	Response(SGA) Global symptoms scor Bloating(a 6-point numerical scale) Abdominal pain(a 6-

Probiotics in the Treatment of IBS

□.	
<u>P</u>	
<u>a</u>	

TABLE 1 | Continued

Study	Year	Country	Type of IBS (%)	diagnostic criteria for	recruitment	Sample size	Sex (Male	e/Female)	Age [years],	Probiotic	Probiotic dosage (CFU/D)	Duration of	Criteria used to define symptom improvement	Outcome
			(70)	IBS		Size	Probiotic	Placebo	mean ± SD		(CF0/D)	therapy	following therapy or response	
		_					//	/						point numerical scale Adverse events
Guyonnet et al. (2007)	2007	France	C:100	Rome II	Primary care	267	29/106	39/93	49.3 ± 11.4	Combination	B. animalis DN173010 (1.25×10 <sup>10</sup> c.f.u./125 g) S. thermophilus	6 weeks	improvement at least 10% vs. baseline	Response(improvement at least 10% vs. baseline) Global symptoms sco
											(1.2×109 c.f.u./125 g) and L. bulgaricus (1.2×109 c.f.u./125 g) b.i.d.			(a 7-pointLikert score Bloating(a 7-Likert score) Abdominal pain(a 7- Likert score)
Drouault- Holowacz et al.	2007	France	D:29 C:29	Rome II	Not stated	100	8/40	16/36	45.4 ± 14	Combination	1 × 10 <sup>10</sup>	4 weeks	Satisfactory relief of global IBS symptoms	Adverse events Satisfactory relief of IB symptoms
(2007)			A:41 non- classified:1%											Abdominal pain(a 4- pointLikert score)
Enck et al. (2008)	2008	Germany	all types	Primary care physicians	Primary care	297	77/72	73/75	49.6 ± 13.6	Enterococcus faecalis DSM16440 and Escherichia coli DSM17252	(3.0-9.0×10 <sup>7</sup> c.f.u./1.5 ml)×0.75 ml t.i.d. for 1 week, then 1.5 ml t.i.d. for weeks 2 and 3, then 2.25 ml t.i.d.	8 weeks	50% improvement in IBS global symptoms,and continuous scale symptoms for IBS	Response(50% improvement in IBS global symptoms) Global symptoms sco (GSS)
											for weeks 3–8			Adverse events
Kajander et al. (2008)	2008	Finland	D:45 C:30 A:25	Rome II	Primary care	86	2/41	4/39	48 ± 13	Combination	1 × 10 <sup>7</sup>	20 weeks	Continuous scale for IBS symptoms	Global symptoms sco Flatulence(a 5-point numerical scale) Distension(a 5-point numerical scale) abdominal pain(a 5- point numerical scale Adverse events
Sinn et al. (2008)	2008	Korea	D:20 C:27.5 M:62.5	Rome III	Secondary care	40	6/14	8/12	44.7 ± 13	L. acidophilus SDC 2012 and 2013	4×10 <sup>9</sup>	4 weeks	Any reduction in abdominal pain score	Response(Any reduction in abdomin- pain score) Abdominal pain(a 6- point numerical scale Adverse events
Zeng et al. (2008)	2008	China	D:100	Rome II	Tertiary care	29	10/4	9/6	45.2 ± 10.7	Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium	S.thermophilus (4×10 <sup>10</sup> c.f.u.), L. bulgaricus (4×10 <sup>9</sup> c.f.u.), L. acidophilus (4×10 <sup>9</sup> c.f.u.), and B. longum	4 weeks	Continuous scale for IBS symptoms	Global symptoms sco Bloating(100-mm VAS Abdominal pain(100- mm VAS) Adverse events
Agrawal et al. (2009)	2009	UK	C:100	Rome III	Tertiary care	34	0/17	0/17	39.4 ± 10.6	Longum Bifidobacterium Iactis DN-173 010 Streptococcus thermophilus	(4×10 <sup>9</sup> c.f.u.) B. lactis DN-173 010 (2.5×10 <sup>10</sup> c.f.u.), S.thermophilus (2.4×10 <sup>9</sup> c.f.u.), L. bulgaricus (2.4×10 <sup>9</sup> c.f.u.),	4 weeks	Continuous scale for IBS symptoms	Global symptoms sc Bloating(a 6-point numerical scale) Flatulence(a 6-poin numerical scale)

Probiotics in the Treatment of IBS

TABLE 1 | Continued

Study	Year	Country	Type of IBS (%)	diagnostic criteria for IBS	recruitment	Sample size	Sex (Male Probiotic		Age [years], mean ± SD	Probiotic	Probiotic dosage (CFU/D)	Duration of therapy	Criteria used to define symptom improvement following therapy or response	Outcome
Enck et al. (2009)	2009	Germany	All types	Kruis score	Primary care	298	76/72	75/75	49.6 ± 13.6	and Lactobacillus bulgaricus E. coli DSM17252	(1.5–4.5×10 <sup>7</sup> c.f.u./ ml) 0.75 ml drops t.i.d. for 1 week, then 1.5 ml t.i.d. for weeks	8 weeks	No longer having IBS symptoms	Abdominal pain(a 6 point numerical scal Response(no longe having IBS symptom General symptom scc Adverse events
Hong et al. (2009)	2009	Korea	D:45.7 C:20 M:8.6 non-	Rome III	tertiary care	70	25/11	22/12	37 ± 14.85	Combination	2-8 4×10 <sup>10</sup>	8 weeks	Reduction of symptom score by at least 50%	Response(Reductior symptom score by least 50%) Adverse events
Williams et al.	2009	UK	classified:25.7 D:11.5C:27	Rome II	Advertising	52	3/25	4/20	39 ± 11.5	Combination	2.5×10 <sup>10</sup>	8 weeks	Continuous scale for IBS	Global symptom sco
(2009) Simrén et al. (2010)	2010	Sweden	A:61.5 D:35 C:15 M:50	Rome II	Tertiary care	74	11/26	11/26	43 ± 15.43	Combination	2×10 <sup>10</sup>	8 weeks	symptoms Adequate relief of their IBS symptoms at least 50% of the weeks	Response(Adequati relief of their IBS symptoms) Global symptom sco Abdominal pain(100 mm VAS)
Choi et al. (2011)	2011	Korea	D:71.6 M:28.4	Rome II	Tertiary care	90	18/17	19/20	40.4 ± 12.9	Saccharomyces boulardii	4×10 <sup>11</sup>	4 weeks	Continuous scale for IBS symptoms	Bloating(100-mm V/ Adverse events Global symptoms sc (7-point Likert scale Bloating(7-point Like scale) Abdominal pain(7-pc
Guglielmetti et al. (2011)	2011	Germany	D:21.3 C:19.7 M:58.2 non- classified:0.8	Rome III	Secondary care and advertising	122	19/41	21/41	38.9 ± 12.75	B. bifidum MIMBb75	1×10 <sup>9</sup>	4 weeks	Improvement in average weekly global IBS symptom score of 1 or more for 50% of weeks, and continuous scale for IBS symptoms	Likert scale) Adverse events Response(Improvem in average weekly glo IBS symptom score o or more for 50% o weeks) Global symptoms sc (7-point Likert scon Bloating(7-point Liker scale)
Michail and Kenche (2011)	2011	USA	D:100	Rome III	Tertiary care	24	5/10	3/6	21.8 ± 17	Combination	9×10 <sup>11</sup>	8 weeks	Continuous scale for IBS symptoms	Abdominal pain(7-pc Likert scale) Adverse events Global symptoms sc (a clinical rating sca GSRS) Bloating(GSRS) Abdominal pain(GSF
Sondergaard et al. (2011)	2011	Denmark and Sweden	all types	Rome II	Primary and secondary care	52	7/20	6/19	51.3± 9.5	Combination	2.5×10 <sup>10</sup>	8 weeks	Adequate relief of IBS symptoms and continuous scale for IBS symptoms	Adverse events Adequate relief of II symptoms Global symptoms so (IBS SSI Francis et

(Continued)

TABLE 1   (	Continued
-------------	-----------

Study	Year	Country	Type of IBS (%)	diagnostic criteria for	recruitment	Sample size	Sex (Male	e/Female)	Age [years],	Probiotic	Probiotic dosage (CFU/D)	Duration of	Criteria used to define symptom improvement	Outcome
			(70)	IBS		5120	Probiotic	Placebo	mean ± SD			therapy	following therapy or response	
	0010	14	D 100		<b>—</b> .:	50	10/10		00.4		1×10 <sup>10</sup>			Abdominal pain(10 mm VAS)
Cha et al. (2012)	2012	Korea	D:100	Rome III	Tertiary care	50	12/13	14/11	39.1 ± 11.76	Combination	IX IU	8 weeks	Adequate relief of their IBS symptoms at least 50% of the weeks and continuous scale for IBS symptoms	Response(Adequa relief of their IBS symptoms at least 5 of the weeks) Global symptoms so (10-point VAS) Abdominal pain(10 point VAS) Bloating(10-point VA
Cui et al. (2012)	2012	China	D:48.3 C:20 M:11.7 non-	Rome III	Tertiary care	60	11/26	7/16	44.66 ± 15.23	Combination	1.5×10 <sup>7</sup>	4 weeks	reduction of symptom score by at least 30%	Adverse events Improvement in IE symptoms
Dapoigny et al. (2012)	2012	France	classified:10 D:30 C:22 M:34 U:14	Rome III	Tertiary care	50	5/20	10/15	47.05± 10.98	Lactobacillus casei rhamnosus LCR35	6×10 <sup>8</sup>	4 weeks	IBS severity score reduced by at least 50%	Response (IBS sev score reduced by least 50%) Adverse events
Ducrotte et al. (2012)	2012	India	all types	Rome III	Primary care	214	70/38	81/25	37.28± 12.6	L. plantarum LP299V DSM 9843	1×10 <sup>11</sup>	4 weeks	Patients rated treatment efficacy as excellent or good	Global assessmer treatment efficar Adverse events
Farup et al. (2012)	2012	Norway	D:37.5 C:6.25 A:56.25	Rome II	Secondary care	28	Not stated	Not stated	50± 11	L. plantarum MF 1298	1×10 <sup>10</sup>	3 weeks	Continuous scale for IBS symptoms	Global symptoms s
Kruis et al. (2012)	2012	Germany	all types	Rome II	Tertiary care	120	12/48	16/44	45.7± 12.4	E. coli Nissle 1917	2.5–25×10 <sup>9</sup> for 4 days then 5–50×10 <sup>9</sup> for 12 weeks	12 weeks	Patients reported contented with treatment	Response (Patier reported contented treatment) Adverse events
Amirimani et al. (2013)	2013	Iran	all types	Rome III	Secondary care	102	21/32	15/24	41.8± 12.5	Lactobacillus reuteri	1×10 <sup>11</sup>	4 weeks	Continuous scale for IBS symptoms	Abdominal pair (questionare) Bloating(question Adverse event
Begtrup et al. (2013)	2013	Denmark	D:40 C:19 M:38 U:2	Rome III	Primary care	131	51/16	46/18	30.52± 9.42	Combination	5.2×10 <sup>10</sup>	6 months	Adequate relief of global IBS symptoms for at least 50% of the time, and continuous scale for IBS symptoms	Response (Adequ relief of global IB symptoms) Global symptoms : Abdominal pain(G IBS) Bloating(GSRS-II Adverse event
Charbonneau et al. (2013)	2013	Ireland	all types	Rome II	Population based	76	8/31	6/31	45.5± 11	B. infantis 35624	1×10 <sup>9</sup>	8 weeks	Continuous scale for IBS symptoms	Global symptor severity(a six-poi scale) Abdominal pain((a point numerical sca Bloating(a six-po numerical scala Adverse events

Study	Year	Country	Type of IBS (%)	diagnostic criteria for	recruitment	Sample size	Sex (Male	e/Female)	Age [years],	Probiotic	Probiotic dosage (CFU/D)	Duration of	Criteria used to define symptom improvement	Outcome
			(70)	IBS		5120	Probiotic	Placebo	mean ± SD		(GFG/D)	therapy	following therapy or response	
Roberts et al. (2013)	2013	UK	C and M	ROME III	Primary care	179	13/75	14/77	44.18± 12.36	Bifidobacterium lactis CNCM I- 2494 S. thermophilus and L. bulgaricus	2.5×10 <sup>10</sup> 2.4×10 <sup>9</sup> 2.4×10 <sup>9</sup>	12 weeks	Subjective global assessment (SGA) of symptom relief	Subjective global assessment (SGA) o symptom relief IBS-SSS Abdominal pain(6 poin Likert scale) Bloating(6 point Liker scale)
Abbas et al. (2014)	2014	Pakistan	D:100	Rome III	Tertiary care	72	27/10	26/9	35.4± 11.9	Saccharomyces boulardii	3×10 <sup>9</sup>	6 weeks	Continuous scale for IBS symptoms	Abdominal pain(a 4- point scale) Bloating(a 4-point sca Adverse events
Jafari et al. (2014)	2014	India	all types	Rome III	Secondary care	108	21/33	22/32	36.7± 11.5	Combination	8×10 <sup>9</sup>	4 weeks	Satisfactory relief of global IBS symptoms for at least 50% of the time	Relief of IBS symptom Abdominal pain(100- mm VAS) Bloating(100-mm VAS
Lorenzo- Zuniga et al. (2014)	2014	Spain	D:100	Rome III	Tertiary care	84	16/39	15/14	46.8± 12.5	Combination	high dose (1-3×10 <sup>10</sup> ) low dose (3-6×10 <sup>9</sup> )	6 weeks	"Considerably relieved" or "completely relieved" of global IBS symptoms for at least 50% of the time	Health-related quality life(a specifc questionnaire ranging from 1-100) Respond(relief of symptoms) Adverse events
Ludidi et al. (2014)	2014	Netherlands	all types	Rome III	Secondary care and advertising	40	6/15	7/12	40.5± 14.4	Combination	5×10 <sup>9</sup>	6 weeks	A 30% or greater improvement in mean symptom composite score (MSS)	Respond(mean symptom composite score MSS)
Pedersen et al. (2014)	2014	Denmark	D:38 C:17.3 A:40.7 non- classified:4	Rome III	Tertiary care	81	14/27	11/29	Not stated	Lactobacillus rhamnosus GG	1.2×10 <sup>10</sup>	6 weeks	Continuous scale for IBS symptoms	IBS-SSS
Shavakhi et al. (2014)	2014	Iran	D:32.6 C:45.7 A:21.7	Rome II	Tertiary care	129	20/46	24/39	36.2± 9.2	Combination	2×10 <sup>8</sup>	2 weeks	Continuous scale for IBS symptoms	Abdominal pain(a 4- point scale) Distension(a 4-point scale)
Sisson et al. (2014)	2014	UK	D:37.6 C:21.5 M:35.5 U:5.4	Rome III	Primary care and secondary care	186	40/84	17/45	38.3± 10.6	Combination	2×10 <sup>8</sup> /kg	12 weeks	Patients reported mild or no symptoms	Respond(IBS-SSS) IBS symptom severit scores (IBS-SSS) Abdominal pain(IBS- SSS) Bloating(IBS-SSS) Adverse events
Stevenson et al. (2014)	2014	South Africa	D:37.6 C:21.5	Rome II	Secondary care	81	2/52	0/27	47.9± 13	Lactobacillus plantarum 299 v	1×10 <sup>10</sup>	8 weeks	Continuous scale for IBS symptoms	IBS symptom severit scores (IBS-SSS) Adverse events
Yoon et al. (2014)	2014	Korea	D:53.1 C40.8 M:6.1	Rome III	Tertiary care	49	11/14	6/18	44.5± 14.3	Combination	1×10 <sup>10</sup>	4 weeks	Global relief of IBS symptoms	Global relief of IBS symptoms Abdominal pain(a 10 point numerical scale Bloating(a 10-point


Probiotics in the Treatment of IBS

Study	Year	Country	Type of IBS	diagnostic criteria for	recruitment	Sample size	e Sex (Male/Female)		Age	Probiotic	Probiotic dosage (CFU/D)	Duration		Outcome
			(%)	IBS		SIZE	Probiotic	Placebo	[years], mean ± SD		(CFU/D)	of therapy	following therapy or response	
	0015		D 05 0			100			00 40 0			0	0	numerical scale) Adverse events
Faghihi et al. (2015)	2015	Iran	D:35.3 C39.6 M:25.1	Rome II	Secondary care	139	Not stated	Not stated	38± 13.3	Escherichia coli Nissle 1917	Not stated	6 weeks	Continuous scale for IBS symptoms	Global symptoms sc (Birmingham IBS Symptom Questionnaire)
Pineton de Chambrun et al. (2015)	2015	France	D:28.5 C46.9 M:24.6	Rome III	Not stated	179	14/72	11/82	44± 13.3	Saccharomyces cerevisiae CNCM I-3856	4×10 <sup>9</sup>	8 weeks	A reduction in the abdominal pain score of 1 arbitrary unit (au) for at least 50% of the time	Improvement in IB symptoms Abdominal pain(7-po Likert scale) Adverse events
Yoon et al. (2015)	2015	Korea	D:48.1 C:18.5 M:21 U:12.4	Rome III	Tertiary care	80	24/17	19/20	59.3± 12.2	Combination	1×10 <sup>10</sup>	4 weeks	Adequate relief of global IBS symptoms	Adequate relief of glo IBS symptoms sc (10-point VAS) Abdominal pain(10 point VAS) Bloating(10-point VA
Lyra et al. (2016)	2016	Finland	D:38.9 C:16.6 M:44 U:0.5	Rome III	Primary care	391	62/198	37/94	47.9± 12.9	L.acidophilus NCFM (ATCC 700396)	low-dose: 1×10 <sup>9</sup> high-dose: 1×10 <sup>10</sup>	12 weeks	Continuous scale for IBS symptoms	IBS symptom sever scores (IBS-SSS) Abdominal pain(IBS SSS) Bloating(IBS-SSS) Adverse events
Majeed et al. (2016)	2016	India	D:100	Rome III	Tertiary care	36	7/11	10/8	35.8± 10.8	Bacillus coagulans MTCC 5856	2×10 <sup>9</sup>	90 days	Continuous scale for IBS symptoms	Abdominal pain (Questionnaire) Bloating(Questionna Adverse events
Mezzasalma et al. (2016)	2016	Italy	C:100	Rome III	Not stated	150	Not stated	Not stated	37.4± 12.5	1: L.acidophilus, L. reuteri 2: L.plantarum, L. rhamnosus, B. animalis subsp. Lactis	1: 1×10 <sup>10</sup> 2: 1.5×10 <sup>10</sup>	60 days	A decrease of abdominal pain of at least 30% compared to the basal condition for at least 50% of the intervention time	Response(the subjereporting a decrease symptoms of at lea 30% compared to t basal condition for least 50% of the intervention time)
Spiller et al. (2016)	2016	France	D:20.8 C47.5 M:31.7	Rome III	Primary care and secondary care	379	31/161	31/156	45.3± 14.9	Saccharomyces cerevisiae I-3856	8×10 <sup>9</sup>	12 weeks	An improvement of 50% of the weekly average "intestinal pain/ discomfort score" compared with baseline average score for at least 4 out of the last 8 weeks of the study	Response Global symptoms so Abdominal pain(8-pr Likert scale) Bloating(8-point Lik scale) Adverse events
Thijssen et al. (2016)	2016	Netherlands	D:30 C:25 A:28.75 U:16.25	Rome II	Secondary care,tertiary care, and advertising	80	13/26	12/29	41.8± 14.1	Lactobacillus casei Shirota	1.3×10 <sup>10</sup>	8 weeks	An mean symptom score (MSS) decrease of at least 30%	Response (An me symptom score(MS decrease of at lea 30%)
Hod et al. (2017)	2017	Israel	D:100	Rome III	Community and secondary	107	0/54	0/53	Not extractable	Combination	5×10 <sup>10</sup>	8 weeks	improvement in symptoms for at least 50% of the tme	Response Adverse events

Probiotics in the Treatment of IBS

TABLE 1   Continued	
---------------------	--


Study	Year	Country	Type of IBS	(%)     criteria for     size     [years],     (CFU/D)     of     symptotic       IBS     Probiotic     Placebo     mean ±     therapy     follow	recruitment	-	Sex (Male	/Female)	-	Probiotic	•		Criteria used to define	Outcome
			(%)		symptom improvement following therapy or response									
					and tertiary care									
lshaque et al. (2018)	2018	Bangladesh	D:100	Rome III	Tertiary care	360	136/45	145/34	31.9 ± 9.9	Combination	8×10 <sup>9</sup>	16weeks	Continuous scale for IBS symptoms	scores (IBS-SSS) Abdominal pain(IBS- SSS) Adverse events
Khodadoostan et al. (2018)	2018	Iran	D:100	Rome III	Secondary care and tertiary care	67	21/12	22/12	34.1 ± 11.0	Combination	2×10 <sup>9</sup>	6 months	Continuous scale for IBS symptoms	Abdominal pain(10- point VAS)
Kim et al. (2018)	2018	Korea	not stated	not stated	Advertising	42	19/11	6/6	32.7 ± 6.6	Lactobacillus gasseri BNR17	low-dose: 1×10 <sup>9</sup> high-dose: 1×10 <sup>10</sup>	4 weeks	Continuous scale for IBS symptoms	Abdominal pain(5-point Likert scale) Bloating(5-point Likert scale)
Preston et al. (2018)	2018	USA	D:46.4 C:35.7 M:18.6	Rome III	Tertiary care	113	47/29	21/16	40.4 ± 13.5	Combination	1×10 <sup>11</sup>	6 weeks	Continuous scale for IBS symptoms	IBS symptom severity scores (IBS-SSS) Abdominal pain(IBS- SSS) Adverse events
Sun et al. (2018)	2018	China	D:100	Rome III	Tertiary care	200	63/42	53/42	43.9 ± 12.7	Clostridium butyricum	5.67×10 <sup>7</sup>	4 weeks	A reduction of ≥50 points of total IBS-SSS score	Response (A reduction of ≥50 points of total IBS-SSS score) IBS symptom severity scores (IBS-SSS) Abdominal pain(IBS- SSS) Bloating(IBS-SSS) Adverse events



and Hu, 2012; Dapoigny et al., 2012; Charbonneau et al., 2013; Jafari et al., 2014; Ludidi et al., 2014; Pedersen et al., 2014; Sisson et al., 2014; Faghihi et al., 2015; Thijssen et al., 2016; Kim et al., 2018; Preston et al., 2018; Sun et al., 2018), and 35 studies did not describe the method of allocation concealment (Gade and Thorn, 1989; Nobaek et al., 2000; Niedzielin et al., 2001; Kajander et al., 2005; Niv et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Simren and Lindh, 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Enck et al., 2008; Zeng et al., 2008; Agrawal et al., 2009; Enck et al., 2009; Williams et al., 2009; Choi et al., 2011; Cha et al., 2012; Cui and Hu, 2012; Dapoigny et al., 2012; Amirimani et al., 2013; Charbonneau et al., 2013; Jafari et al., 2014; Ludidi et al., 2014; Pedersen et al., 2014; Shavakhi et al., 2014; Stevenson et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Maieed et al., 2016; Thiissen et al., 2016; Hod et al., 2017; Ishaque et al., 2018; Khodadoostan et al., 2018; Preston et al., 2018; Sun et al., 2018), which lead to an unclear risk of selection bias. The risk of blinding the participants and personnel was low, except two studies (Zeng et al., 2008; Pedersen et al., 2014) were at high risk and one (Cui and Hu, 2012) was unclear. The risk of outcome assessment was mostly unclear. However, one study (Pedersen et al., 2014) was an unblinded controlled trial, leading to a high risk of performance and detection bias. Attrition bias, reporting bias, and other biases were low.

### Efficacy of Probiotics on IBS Symptoms Improvement or Response

Thirty-five RCTs (Gade and Thorn, 1989; Nobaek et al., 2000; Niedzielin et al., 2001; Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Enck et al., 2008; Sinn et al., 2008; Enck et al., 2009; Hong et al., 2009; Simrén et al., 2010; Guglielmetti et al., 2011; Sondergaard et al., 2011; Cha et al., 2012; Cui and Hu, 2012; Dapoigny et al., 2012; Ducrotte et al., 2012; Kruis et al., 2012; Begtrup et al., 2013; Roberts et al., 2013; Jafari et al., 2014; Lorenzo-Zuniga et al., 2014; Ludidi et al., 2014; Sisson et al., 2014; Yoon et al., 2014; Pineton de Chambrun et al., 2015; Yoon et al., 2015; Spiller et al., 2016; Mezzasalma et al., 2016; Thijssen et al., 2016; Hod et al., 2017; Sun et al., 2018) with 4,392 patients reported overall IBS symptoms improvement or response as a dichotomous outcome. There were two (Lorenzo-Zuniga et al., 2014; Mezzasalma et al., 2016) of these RCTs examining two different dose groups and one (Whorwell et al., 2006) examining three different dose groups. One (Gade and Thorn, 1989) RCT did not mention the dose of probiotics, so it was not included in the subgroup analysis of probiotics dose. Overall, 1,171(49.5%) of 2,367 patients in the group of probiotics declared symptoms improvement or response after therapy, compared with 644 (31.8%) of 2,025 in the placebo group. The RR of IBS symptoms improvement or response was 1.52(95% CI 1.32-1.76), with high heterogeneity ( $I^2 = 71\%$ , P < 0.001; Figure 4). The funnel plot suggested the existence of asymmetry (Egger test, P = 0.094; Figure S1), indicating possible publication bias. While 19 RCTs (Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; Drouault-Holowacz et al., 2008; Sinn et al., 2008; Hong et al., 2009; Simrén et al., 2010; Guglielmetti et al., 2011; Sondergaard et al., 2011; Ducrotte et al., 2012; Kruis et al., 2012; Begtrup et al., 2013; Roberts et al., 2013;



Sisson et al., 2014; Lorenzo-Zuniga et al., 2014; Pineton de Chambrun et al., 2015; Mezzasalma et al., 2016; Spiller et al., 2016; Hod et al., 2017) with low bias risk were assessed, the effect was still significant (RR = 1.59; 95% CI 1.25–2.04).

In the subgroup of duration, 18 studies (Gade and Thorn, 1989; Nobaek et al., 2000; Niedzielin et al., 2001; Kim et al., 2005; Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Sinn et al., 2008; Guglielmetti et al., 2011; Cui and Hu, 2012; Dapoigny et al., 2012; Ducrotte et al., 2012; Jafari et al., 2014; Lorenzo-Zuniga et al., 2014; Ludidi et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Sun et al., 2018) evaluated a shorter duration (< 8 weeks) and 17 studies (Kim et al., 2003; Kajander et al., 2005; Enck et al., 2008; Enck et al., 2009; Hong et al., 2009; Simrén et al., 2010; Sondergaard et al., 2011; Cha et al., 2012; Kruis et al., 2012; Begtrup et al., 2013; Roberts et al., 2013; Sisson et al., 2014; Pineton de Chambrun et al., 2015; Mezzasalma et al., 2016; Spiller et al., 2016; Thijssen et al., 2016; Hod et al., 2017) used a longer duration ( $\geq 8$  weeks). The RR of group with less than 8 weeks was 1.55 (95% CI 1.27-1.89; Figure 4), and the RR of group with more than 8 weeks was 1.52 (95% CI 1.23-1.88), with significant heterogeneity ( $I^2 = 74\%$ , P < 0.01;  $I^2 = 69\%$ , P < 0.01, respectively). In the subgroup of probiotics dose, high doses (daily dose of probiotics  $\geq 10^{10}$ ) were assessed in 21 trials (Niedzielin et al., 2001; Kim et al., 2003; Kim et al., 2005; Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Hong et al., 2009; Simrén et al., 2010; Sondergaard et al., 2011; Cha et al., 2012; Ducrotte et al., 2012; Kruis et al., 2012; Begtrup et al., 2013; Roberts et al., 2013; Sisson et al., 2014; Lorenzo-Zuniga et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Mezzasalma et al., 2016; Thijssen et al., 2016; Hod et al., 2017). A significant effect on symptoms (RR = 1.51; 95% CI 1.20–1.91; **Figure S2**) and statistically significant heterogeneity ( $I^2 = 77\%$ , P < 0.01) were suggested. Low doses (daily dose of probiotics  $< 10^{10}$ ) were evaluated in 15 trials (Nobaek et al., 2000; Kajander et al., 2005; Whorwell et al., 2006; Enck et al., 2008; Sinn et al., 2008; Enck et al., 2009; Guglielmetti et al., 2011; Cui and Hu, 2012; Dapoigny et al., 2012; Jafari et al., 2014; Lorenzo-Zuniga et al., 2014; Ludidi et al., 2014; Pineton de Chambrun et al., 2015; Spiller

et al., 2016; Sun et al., 2018). A significant effect on symptoms (RR = 1.56; 95% CI 1.33–1.83) and significant heterogeneity were also detected ( $I^2 = 54\%$ , P < 0.01). In the subgroup of probiotics type, there were 15 studies using single probiotics (Gade and Thorn, 1989; Nobaek et al., 2000; Niedzielin et al., 2001; Whorwell et al., 2006; Sinn et al., 2008; Enck et al., 2009; Guglielmetti et al., 2011; Dapoigny et al., 2012; Ducrotte et al., 2012; Kruis et al., 2012; Pineton de Chambrun et al., 2015; Mezzasalma et al., 2016; Spiller et al., 2016; Thijssen et al., 2016; Sun et al., 2018) and 21 studies using combination probiotics (Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Enck et al., 2008; Hong et al., 2009; Simrén et al., 2010; Sondergaard et al., 2011; Cha et al., 2012; Cui and Hu, 2012; Begtrup et al., 2013; Roberts et al., 2013; Jafari et al., 2014; Lorenzo-Zuniga et al., 2014; Ludidi et al., 2014; Sisson et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Mezzasalma et al., 2016; Hod et al., 2017). The RR of single and combination group was 1.76 (95% CI 1.37-2.25; Figure S3) and 1.39 (95% CI 1.18-1.65), respectively. The  $I^2$  of the single probiotics subgroup was 69% (P < 0.01), and combination probiotics subgroup was 60% (P < 0.01)0.01), suggesting statistically significant heterogeneity. In the subgroup of geographic position, we assigned 2 trials (Kim et al., 2003; Kim et al., 2005) in USA to the North America group; five comparisons of three separate papers (Whorwell et al., 2006; Roberts et al., 2013; Sisson et al., 2014) in UK, five trials (Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Dapoigny et al., 2012; Pineton de Chambrun et al., 2015; Spiller et al., 2016) in France, and two trials (Ludidi et al., 2014; Thijssen et al., 2016) in Netherlands to the Western Europe group; two comparisons of one papers (Lorenzo-Zuniga et al., 2014) in Spain and two comparisons of one papers (Mezzasalma et al., 2016) in Italy to the South Europe group; two trials (Gade and Thorn, 1989; Begtrup et al., 2013) in Denmark, two trials (Nobaek et al., 2000; Simrén et al., 2010) in Sweden, one trials (Sondergaard et al., 2011) in Denmark and Sweden, and one trials (Kajander et al., 2005) in Finland to the Northern Europe group; one trials (Niedzielin et al., 2001) in Poland and four trials (Enck et al., 2008; Enck et al., 2009;

Study or Subgroup		Total	Events	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.2.1 Intervention duration <		1210		2-3	10000		
Gade 1989	26	32	9	22	2.7%	1.99 [1.17, 3.37]	
Nobaek 2000 Niedzielin 2001	9 9	25 20	5 3	27 20	1.5% 1.1%	1.94 [0.75, 5.02] 3.00 [0.95, 9.48]	
Kim 2005	11	20	8	20	2.1%	1.38 [0.67, 2.81]	
Whorwell 2006 (1)	43	90	42	92	3.6%	1.05 [0.77, 1.43]	+
Whorwell 2006 (2)	63	90	42	92	3.8%	1.53 [1.18, 1.99]	+
Whorwell 2006 (3)	38	90	42	92	3.5%	0.92 [0.67, 1.28]	-+
Drouault-Holowacz 2007	20	48	22	52	3.0%	0.98 [0.62, 1.56]	
Guyonnet 2007	85	135	75 7	132	4.0%	1.11 [0.91, 1.35]	T
Sinn 2008 Guglielmetti 2011	16 34	20 60	13	20 62	2.3% 2.7%	2.29 [1.21, 4.32] 2.70 [1.59, 4.60]	
Cui 2012	24	37	7	23	2.2%	2.13 [1.10, 4.13]	
Dapoigny 2012	7	25	10	26	1.8%	0.73 [0.33, 1.61]	
Ducrotte 2012	84	108	9	106	2.3%	9.16 [4.86, 17.25]	
Jafari 2014	46	54	25	54	3.6%	1.84 [1.35, 2.50]	
Lorenzo-Zuniga 2014 (4)	10	24	6	24	1.7%	1.67 [0.72, 3.86]	
Lorenzo-Zuniga 2014 (5) Ludidi 2014	8 4	25 21	6 7	24 19	1.6% 1.3%	1.28 [0.52, 3.14] 0.52 [0.18, 1.49]	
Yoon 2014	17	25	9	24	2.5%	1.81 [1.01, 3.25]	
Yoon 2015	29	39	26	42	3.6%	1.20 [0.89, 1.62]	+
Sun 2018	47	105	29	95	3.3%	1.47 [1.01, 2.12]	
Subtotal (95% CI)		1097		1072	54.3%	1.55 [1.27, 1.89]	•
Total events	630		402				
Heterogeneity: Tau <sup>2</sup> = 0.13; Cl Test for overall effect: Z = 4.27			U (P < U.U	0001);	1*= /4%		
rest for overall ellect. Z = 4.27	(P < 0.00	51)					
1.2.2 Intervention duration >	Bwk						
Kim 2003	4	12	5	13	1.3%	0.87 [0.30, 2.49]	
Kajander 2005	31	41	17	40	3.2%	1.78 [1.19, 2.65]	
Enck 2008	102	149	56	148	3.9%	1.81 [1.43, 2.29]	-
Enck 2009 Hong 2009	27 20	148 36	7 17	150 34	1.8% 3.0%	3.91 [1.76, 8.70]	
Simrén 2010	10	30	14	34	2.2%	1.11 [0.71, 1.73] 0.71 [0.36, 1.40]	
Sondergaard 2011	10	27	7	25	1.8%	1.32 [0.60, 2.94]	
Cha 2012	12	25	3	25	1.2%	4.00 [1.28, 12.47]	
Kruis 2012	27	60	23	60	3.1%	1.17 [0.77, 1.80]	
Begtrup 2013	35	67	26	64	3.3%	1.29 [0.88, 1.87]	
Roberts 2013 Sisson 2014	22 33	88 124	25 9	91 62	2.8%	0.91 [0.56, 1.49]	
Pineton de Chambrun 2015	33 54	124	44	62 93	2.2%	1.83 [0.94, 3.59] 1.33 [1.01, 1.74]	
Mezzasalma 2016 (6)	34	50	7	50	2.1%	4.86 [2.38, 9.91]	
Mezzasalma 2016 (7)	38	50	7	50	2.1%	5.43 [2.68, 10.98]	
Spiller 2016	57	177		175	3.5%	1.20 [0.87, 1.66]	+-
Thijssen 2016	14	39	12	41	2.3%	1.23 [0.65, 2.31]	
Hod 2017	11	54	13	53	2.1%	0.83 [0.41, 1.69]	
Subtotal (95% CI)	541	1270		1211	45.7%	1.52 [1.23, 1.88]	▼
Total events Heterogeneity: Tau <sup>2</sup> = 0.12; Cl		df = 1	339 7 (P < 0 0	00011	$ ^2 = 69\%$		
Test for overall effect: Z = 3.89			0.0		5575		
Total (95% CI)		2367		2283	100.0%	1.53 [1.33, 1.77]	•
Total events	1171	7 16	741	00004	12 - 74 ~		
Heterogeneity: Tau <sup>2</sup> = 0.12; Cl Test for overall effect: Z = 5.87			38 (P < 0.	00001	r, i* = 71%		0.01 0.1 1 10 100
Test for subgroup differences			1 (P = 0.0)	1) 12-	0%		Favours placebo Favours probiotics
Footnotes	0.		0.5		- ~		
(1) doses of probiotic (1 × 10 <sup>6</sup>	5						
(2) doses of prohiotic (1 x 10°	1						
<ul> <li>(3) doses of probiotic (1 × 10<sup>1</sup></li> <li>(4) high dose</li> </ul>	6)						
(4) high dose	·						
(5) low dose							
(6) F1 (7) F2							
(7)12							

Guglielmetti et al., 2011; Kruis et al., 2012) in Germany to the Central Europe group; five trials (Sinn et al., 2008; Hong et al., 2009; Cha et al., 2012; Yoon et al., 2014; Yoon et al., 2015) in Korea and two trials (Cui and Hu, 2012; Sun et al., 2018) in China to the East Asian group; one trials (Hod et al., 2017) in Israel to the West Asian group; and two trials (Ducrotte et al., 2012; Jafari et al., 2014) in India to the South Asian group. There was a statistically significant benefit in favor of probiotics in North America group (RR = 1.19; 95% CI 0.66–2.15; **Figure 5**), with no significant heterogeneity noted between the studies( $I^2 = 0\%$ , P = 0.48), West Europe group (RR = 1.15; 95% CI 1.01–1.30;  $I^2 = 25\%$ , P = 0.20), Northern Europe group(RR = 1.45; 95% CI 1.10–1.91;  $I^2 = 33\%$ , P = 0.19) and East Asian group(RR = 1.55; 95% CI 1.21–1.98;  $I^2 = 39\%$ , P = 0.13).

# Efficacy of Probiotics on Global IBS Symptoms Scores

There were 29 separate trials (Kim et al., 2003; Kajander et al., 2005; Niv et al., 2005; O'Mahony et al., 2005; Simren and Lindh, 2006; Whorwell et al., 2006; Kajander et al., 2008; Zeng et al., 2008; Agrawal et al., 2009; Williams et al., 2009; Simrén et al., 2010; Choi et al., 2011; Guglielmetti et al., 2011; Michail and


Study or Subgroup	probiotics Events Total	placeb Events		eight I	Risk Ratio V, Random, 95% Cl	Risk IV, Rand	om, 95% Cl
1.4.1 North America Kim 2003	4 12	5		1.3%	0.87 [0.30, 2.49]		
Kim 2005 Subtotal (95% CI)	11 24 36	8		2.1% 3.4%	1.38 [0.67, 2.81] 1.19 [0.66, 2.15]	-	•
Total events	15	13					
Heterogeneity: Tau <sup>2</sup> = 0.00; Test for overall effect: Z = 0.		P = 0.48);	1~= 0%				
1.4.2 Western Europe					1953-1970-198, 200		
Whorwell 2006 (1) Whorwell 2006 (2)	43 90 63 90	42 42		3.6% 3.8%	1.05 [0.77, 1.43] 1.53 [1.18, 1.99]	-	-
Whorwell 2006 (3)	38 90	42		3.5%	0.92 [0.67, 1.28]		<u>+</u>
Drouault-Holowacz 2007 Guyonnet 2007	20 48 85 135	22 75		3.0% 4.0%	0.98 [0.62, 1.56] 1.11 [0.91, 1.35]		F
Dapoigny 2012 Roberto 2012	7 25 22 88	10		1.8%	0.73 [0.33, 1.61]		<u></u>
Roberts 2013 Sisson 2014	33 124	25 9	62	2.8% 2.2%	0.91 [0.56, 1.49] 1.83 [0.94, 3.59]		<u> </u>
Ludidi 2014 Pineton de Chambrun 2015	4 21 54 86	7 44		1.3% 3.7%	0.52 [0.18, 1.49] 1.33 [1.01, 1.74]		+
Spiller 2016	57 177	47	175	3.5%	1.20 [0.87, 1.66]		
Thijssen 2016 Subtotal (95% CI)	14 39 1013	12		2.3% 5 <b>.5</b> %	1.23 [0.65, 2.31] 1.15 [1.01, 1.30]		•
Total events Heterogeneity: Tau <sup>2</sup> = 0.01;	440 Chi <sup>2</sup> = 14.64, df = 1	377 1 (P = 0.2	0): 1² = 25	96			
Test for overall effect: Z = 2.							
1.4.3 Southern Europe	8 25				1 00 10 50 0 4 11	_	
Lorenzo-Zuniga 2014 (4) Lorenzo-Zuniga 2014 (5)	8 25 10 24	6 6		1.6% 1.7%	1.28 [0.52, 3.14] 1.67 [0.72, 3.86]	-	
Mezzasalma 2016 (6) Mezzasalma 2016 (7)	34 50 38 50	7		2.1% 2.1%	4.86 [2.38, 9.91] 5.43 [2.68, 10.98]		
Subtotal (95% CI)	149			7.5%	2.85 [1.41, 5.79]		•
Total events Heterogeneity: Tau <sup>2</sup> = 0.36;		26 P = 0.02);	l² = 69%				
Test for overall effect: Z = 2.							
1.4.4 Northern Europe Gade 1989	26 32	9	22	2.7%	1.99 [1.17, 3.37]		
Kajander 2005	31 41	17	40	3.2%	1.78 [1.19, 2.65]		
Nobaek 2000 Simrén 2010	9 25 10 37	5 14		1.5% 2.2%	1.94 [0.75, 5.02] 0.71 [0.36, 1.40]		_
Sondergaard 2011 Begtrup 2013	10 27 35 67	7 26	25	1.8% 3.3%	1.32 [0.60, 2.94]	-	
Subtotal (95% CI)	229			4.8%	1.29 [0.88, 1.87] 1.45 [1.10, 1.91]		•
Total events Heterogeneity: Tau <sup>2</sup> = 0.04;	121 Chi <sup>2</sup> = 7.44, df = 5	78 P = 0.19);	² = 33%				
Test for overall effect: Z = 2.							
1.4.5 Central Europe	0 20	2	20	1.10	2 00 10 05 0 40		
Niedzielin 2001 Enck 2008	9 20 102 149	3 56	148	1.1% 3.9%	3.00 (0.95, 9.48) 1.81 (1.43, 2.29)		+
Enck 2009 Guglielmetti 2011	27 148 34 60	7 13		1.8% 2.7%	3.91 [1.76, 8.70] 2.70 [1.59, 4.60]		
Kruis 2012 Subtotal (95% CI)	27 60 437	23	60	3.1% 2.6%	1.17 [0.77, 1.80] 2.05 [1.41, 2.98]		-
Total events	199	102			2.05 [ 1.4 1, 2.96]		•
Heterogeneity: Tau <sup>2</sup> = 0.10; Test for overall effect: Z = 3.		(P = 0.03)	); l* = 629	6			
1.4.6 East Asian							
Sinn 2008 Hong 2009	16 20 20 36	7 17		2.3% 3.0%	2.29 [1.21, 4.32] 1.11 [0.71, 1.73]	-	
Cha 2012	12 25	3	25	1.2%	4.00 [1.28, 12.47]		
Cui 2012 Yoon 2014	24 37 17 25	7 9		2.2% 2.5%	2.13 [1.10, 4.13] 1.81 [1.01, 3.25]		
Yoon 2015 Sun 2018	29 39 47 105	26 29		3.6% 3.3%	1.20 [0.89, 1.62]		+
Subtotal (95% CI)	287			3.3% 8.2%	1.55 [1.21, 1.98]		•
Total events Heterogeneity: Tau <sup>2</sup> = 0.04;	165 Chi <sup>2</sup> = 9.78, df = 6	98 P = 0.13);	l² = 39%				
Test for overall effect: Z = 3.							
1.4.7 West Asia Hod 2017	11 54	13	53	2.1%	0.83 [0.41, 1.69]		<u> </u>
Subtotal (95% CI)	54			2.1% 2.1%	0.83 [0.41, 1.69] 0.83 [0.41, 1.69]		
Total events Heterogeneity: Not applicab	11 le	13					
Test for overall effect: Z = 0.							
1.4.8 South Asia	· ·		105	0.00			
Ducrotte 2012 Jafari 2014	84 108 46 54		54	2.3% 3.6%	9.16 [4.86, 17.25] 1.84 [1.35, 2.50]		-
Subtotal (95% CI) Total events	162 130	34	160	5.9%	4.00 [0.83, 19.29]		
Heterogeneity: Tau <sup>2</sup> = 1.22;	Chi <sup>2</sup> = 19.97, df = 1		001); l²=	95%			
Test for overall effect: Z = 1.							
Total (95% CI) Total events	2367 1171	741	2283 10	0.0%	1.53 [1.33, 1.77]		•
Heterogeneity: Tau <sup>2</sup> = 0.12; Test for overall effect: Z = 5.	Chi <sup>2</sup> = 130.77, df =		00001); P	= 71%		0.01 0.1	1 10 100
Test for subgroup difference		= 7 (P = 0	.005), I² =	65.8%		Favours (placebo)	Favours (probiotics)
Footnotes	_6.						
<ul> <li>(1) doses of probiotic (1 × 1</li> <li>(2) doses of probiotic (1 × 1</li> </ul>	~ <sup>8</sup> \						
(2) doses of problotic (1 × 1 (3) doses of problotic (1 × 1 (4) low dose	0'0)						
(5) high dose (6) F1							
(6) F1 (7) F2							

Kenche, 2011; Sondergaard et al., 2011; Cha et al., 2012; Farup et al., 2012; Charbonneau et al., 2013; Begtrup et al., 2013; Roberts et al., 2013; Sisson et al., 2014; Pedersen et al., 2014; Stevenson et al., 2014; Faghihi et al., 2015; Yoon et al., 2015; Lyra et al., 2016; Spiller et al., 2016; Ishaque et al., 2018; Sun et al., 2018) including 35 comparisons with 3,726 patients reporting the efficacy of probiotics on global IBS symptoms scores. One (Spiller et al., 2016) of these RCTs examining two different dose groups and one (Whorwell et al., 2006) examining three different dose groups. There was a trial (Faghihi et al., 2015) did not mention the dose of probiotics, so it was not included in the subgroup analysis of probiotics dose. Two types of probiotics were used in one trial (O'Mahony et al., 2005), and three subtypes of IBS, including IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed patterns of constipation and diarrhea (IBS-M), were detected separately in one RCT (Spiller et al., 2016). Probiotics had a statistically

significant effect on improving the global IBS symptoms vs. placebo (SMD = -1.8; 95% CI -0.30 to -0.06; **Figure 6**). Heterogeneity was significant ( $I^2 = 65\%$ , P < 0.001). There was no significant asymmetry in funnel plot (Egger test, P = 0.689; **Figure S4**), indicating no proof of publication bias.

In the subgroup of duration, 11 comparisons (Simren and Lindh, 2006; Whorwell et al., 2006; Zeng et al., 2008; Agrawal et al., 2009; Choi et al., 2011; Guglielmetti et al., 2011; Farup et al., 2012; Pedersen et al., 2014; Faghihi et al., 2015; Yoon et al., 2015; Sun et al., 2018) evaluated a shorter treatment duration (< 8 weeks). There was a beneficial effect on global IBS symptoms scores with probiotics (SMD -0.09; 95% CI -0.20 to 0.02) and low heterogeneity was found ( $I^2 = 10\%$ , P = 0.12). In the subgroup of probiotics dose, no significant differences were found, as shown in **Figure S5**. In the subgroup of probiotics type, 14 comparisons (Niv et al., 2005; O'Mahony et al., 2005; Simren and Lindh, 2006; Whorwell et al., 2006; Choi et al., 2011; Guglielmetti et al., 2011;

Whorwell 2006 (t) 6.09 2.27 90 5.91 2.49 92 3.88 0.07 [6.2, 3.96] Whorwell 2006 (t) 6.22 2.47 90 5.91 2.49 92 3.88 0.12 [6.4, 0.6] Agrawal 2006 2.1 1.4 14 5.22 1.26 15 1.78 0.12 [6.4, 0.6] Agrawal 2008 2.1 1.4 13 17 30 1080 11 21 1.98 0.34 14.01, 0.34 Cupielemell 2011 2.75 13.7 9 205 11.44 7 1.15 0.24 14.16 0.34 Cupielemell 2011 2.75 13.7 9 205 11.44 7 1.15 0.22 [6.4, 0.6] Faiphill 2015 0.7.7 16.2 0.19 1.45 0.14 1.28 1.40 2.98 0.00 [1.24, 0.57 14.52, 0.6] Faiphill 2015 0.7.7 16.3 0.10 12.9 1.14 14 2.8 1.44 0.2.98 0.00 [1.24, 0.53 0.44, 0.41 0.43 0.44 0.41 0.84 0.39 0.10 [1.24, 0.52, 0.6] Faiphill 2015 0.4.7 16.20 0.19 1.47 0.4.1 0.2.98 0.00 [1.24, 0.53 0.44 0.41 0.43 0.44 0.41 0.84 0.39 0.10 [1.24, 0.52, 0.6] Faiphill 2015 0.4.7 16.50 0.15 12.2 12 1.46 9 13 1.5% 0.27 [1.16, 0.43 0.44 0.41 0.82 0.39 0.44 0.41 0.82, 0.02 0.44 0.41 0.82, 0.02 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.41 0.82 0.39 0.44 0.41 0.82, 0.02 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.41 0.84 0.39 0.46 0.41 0.43, 0.02 0.44 0.42, 0.06 0.44 0.41 0.84 0.39 0.46 0.41 0.42, 0.02 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.42, 0.06 0.44 0.42, 0.07 0.44 0.42, 0.07 0.44 0.42, 0.07 0.44 0.42, 0.07 0.44 0.42, 0.07 0.44 0.42, 0.07 0.44 0.42, 0.07 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.44 0.2 0.45 0.44 0.44 0.44 0.44 0.44 0.44 0.44	Study or Subgroup 2.2.1 Intervention du Simren 2006		SD Tota		118	29	Weight 2.5%	V, Random, 95% Cl	IV, Random, 95% Cl
Whorwell 2006 (c) 6. 06 2.37 90 5.91 2.49 92 38% $-0.35 (6.44 - 0.06)$ Zeng 2008 6.07 1.14 14 6.522 1.26 15 1.7% $-0.12 (4.05, 0.61)$ Char 2011 150.21 01.36 24 172 0.21 2.15 17 1.9% $-0.12 (4.05, 0.61)$ Char 2011 150.21 01.36 24 172 0.25 14 0.25 14 0.25 14 0.21 0.25 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21									
$ \begin{array}{c} 2 \text{ arg } 2008 & 5.07 & 1.14 & 14 & 5.22 & 1.26 & 15 & 1.78 & -0.12 \ 10.85 \ 0.611 \\ \text{Agrives} 2008 & 2.4 \ 16.73 & 17 & 2018 \ 10.17 \ 1.98 & -0.32 \ 1.01 \ 0.32 \ 10.16 \ 10.16 \$									
A $q_{1}^{\text{max}} al 2009$ 24 16.73 17 30 1801 17 1.9% -0.34 [-101, 0.34] Chai 2011 150.23 101.96 34 172 99.51 32.7% -0.27 [-0.69, 0.27] Guglernetli 2011 207 172 60 227 114 62 34.8% -0.071 [-0.5, 0.19] Faup 2012 175 137 9 205 124 17 118 -0.22 [-11, 0.7] Pedersen 2014 2.9 1.1 41 2.8 14 40 2.9% -0.09 [-0.4, 0.03] U 2.9 114 13.88 39 14.78 14.19 42 2.9% -0.09 [-0.4, 0.03] Sunzolfs 16.65 105 1986 70.38 95 3.7% -0.03 [-0.4, 0.01] Heterogenetly Tat'= 0.00, Ch <sup>±</sup> = 13.7, d <sup>±</sup> = 12 (p = 0.35), P = 10% Test for versal effect 2 = 1.5 GP = 0.12) Heterogenetized for example to the state of the state									
Choi 2011 150.23 101.86 34 172 9951 33 2.7% -0.21 [0.96, 0.27] Faup 2012 175 137 9 205 124 7 11% -0.22 [1.21, 0.78] Pedress 2014 2.9 11 41 2.8 1 40 2.9% 0.00 [0.34, 0.34] Oxon 2015 14.41 13.88 39 14.78 14.19 42 2.9% -0.03 [0.40, 0.34] Subtoal (9% C) 663 66.56 105 199.6 70.36 95 3.8% -0.34 [0.52, 0.06] Subtoal (9% C) 665 105 199.6 70.36 95 3.8% -0.34 [0.52, 0.06] Subtoal (9% C) 665 105 199.6 70.36 95 3.8% -0.34 [0.52, 0.06] Netrogeneky, Tar = 0.00, Ch <sup>2</sup> = 3.27, d= 12 ( $P = 0.35$ ), $P = 10\%$ Testfor overall effect 2.1.53 ( $P = 0.12$ ) 2.2.2 Intervention duration $\Rightarrow$ 8wk Kina 2005 204 132 49 21 20 134 40 2.9% -0.47 [0.31, -0.33] Kiandare 2005 204 132 49 21 20 132 49 21 20 35 2.4% -0.47 [0.31, -0.33] Netabol 2005 ( $P = 0.12$ ) 2.2.2 Intervention duration $\Rightarrow$ 8wk Kina 2005 204 132 49 21 20 30 2.5 2 45 0.4% -0.47 [1.50, 0.37] Kianadre 2005 24 16.73 43 30 1801 43 2.9% -0.34 [-0.7, 0.8] Williams 2008 7.64 112 2.48 181 448 2.2% -0.34 [-0.7, 0.8] Williams 2008 7.64 112 2.48 181 448 2.2% -0.34 [-0.7, 0.33] [-0.0, -0.34] Notes 2005 7.04 16.7 2.48 15 1.3 0.8 9 1.4% -0.24 [-0.2, 0.36] [-0.0, -0.34] Kianadre 2005 0.24 16.73 42 28 10.66 2.7% -0.33 [-0.0, 0.24] Kianadre 2005 7.64 17.2 28 118 148 2.2% -0.34 [-0.7, 0.8] Williams 2008 7.64 11.2 28 10.66 2.7 2.8% -0.33 [-0.0, 0.34] Simerá 2010 1.2 0.8 15 1.3 0.8 9 7.2 8% -0.33 [-0.0, 0.34] Kianadre 2013 1.56 1.21 54 1.97 1.65 44 3.1% -0.29 [-0.6], 0.11 Sondergaard 2011 1.2 0.8 15 1.3 0.8 9 7.48 2.2 2.8% -0.33 [-0.0, 0.4] Kianadre 2013 1.56 1.21 54 1.97 1.65 2.47 % -0.33 [-0.0, 0.4] Kianadre 2013 1.56 1.21 54 1.97 1.65 44 3.1% -0.29 [-0.6], 0.13 Since 1.6 (% 7.3 4 62 2.6 4.8 98 3.7% -0.23 [-0.0, 0.4] Kianadre 2016 (% 8.4 5.5 41 7.9 4.2 238 2.9% -0.03 [-0.40, 0.4] Lyra 2016 (% 6.48 4.5 54 1 7.9 4.2 238 2.9% -0.03 [-0.40, 0.4] Lyra 2016 (% 7.3 4 62 2.6 4.4 8.98 3.7% -0.29 [-0.50, 0.1] Test or weall effect 2.= 1.39 (P = 0.000) Test or weall effect 2.= 1.39 (P = 0.000) Test or weall effect 2.= 1.30 (P = 0.000) Test or weall effect 2.= 1.30 (P = 0.000) Te									
$ \begin{array}{c} GupleInvelti_{211} \ \ 207 \ \ 128 \ \ 60 \ \ 227 \ \ 114 \ \ 62 \ \ 3.48 \ \ \ -0.17 \ \ (6.25, 0.19) \\ Fauph 2012 \ \ 175 \ \ 137 \ \ 92 \ \ 525 \ \ 124 \ \ 140 \ \ 298 \ \ \ 0.09 \ \ 0.34 \ \ 0.53 \\ Outp 0.34, 0.54 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$									
$ \begin{array}{c} \mbox{Farip} 2012 & 175 & 137 & 9 & 205 & 124 & 7 & 118 & -0.22 (\pm 121, 0.78) \\ \mbox{Fach} 121 & 2.8 & 1 & 40 & 2.98 & -0.02 (\pm 121, 0.78) \\ \mbox{Fach} 13.68 & 35 & 1.78 & 4.18 & 4.2 & 9.8 & -0.09 (\pm 0.34, 0.53) \\ \mbox{Subtoal} (95 V_{1}) & 68.5 & 67.3 & 55.8 & -0.00 (\pm 0.34, 0.34) \\ \mbox{Subtoal} (95 V_{1}) & 68.5 & 67.3 & 55.8 & -0.34 (\pm 0.52, -0.66) \\ \mbox{Hetergeneiky} Tax^2 & 0.00 (\pm 13.26, 118.6 & 70.36) & 95 & 3.88 & -0.34 (\pm 0.52, -0.66) \\ \mbox{Hetergeneiky} Tax^2 & 0.00 (\pm 13.26, 112 \pm 0.25) (\pm 10.8) \\ \mbox{Factor} 13.6 & 67.6 & 105 & 189.6 & 70.36 & 95 & 3.88 & -0.34 (\pm 0.52, -0.66) \\ \mbox{Hetergeneiky} Tax^2 & 0.00 (\pm 13.26, 12 \pm 12.4 \pm 0.35) (\pm 10.8) \\ \mbox{Kajancier} 2005 & 204 & 13.46 & 41 & 20.8 & 13.44 & 40 & 2.98 & -0.47 (\pm 0.51, -0.33) \\ \mbox{Value} 2005 & 204 & 13.46 & 41 & 20.8 & 13.576 & 18 & 2.09 & -0.28 (\pm 0.36, 0.51) \\ \mbox{Value} 2005 & (204 & 13.26, 9 & 21 & 230 & 15.76 & 18 & 2.09 & -0.28 (\pm 0.36, 0.51) \\ \mbox{Value} 2005 & (204 & 13.46 & 91 & 10.8 & 15.76 & 18 & 2.09 & -0.28 (\pm 0.36, 0.51) \\ \mbox{Value} 2005 & (204 & 13.26, 9 & 21 & 230 & 15.76 & 18 & 2.09 & -0.28 (\pm 0.36, 0.51) \\ \mbox{Value} 2005 & (704 & 124 & 228 & 918 & 14.48 & 2.29 & -0.47 (\pm 0.31, 0.03) \\ \mbox{Value} 2005 & 7.0 & 41.67, 2.43 & 3.0 & 91.6 & 42 & 2.278 & -0.32 (\pm 0.77, 0.08) \\ \mbox{Value} 2010 & 3.3 & 0.88 & 37 & 3.8 & 0.68 & 37 & 2.78 & -0.32 (\pm 0.77, 0.08) \\ \mbox{Value} 2010 & 1.2 & 0.8 & 15.3 & 0.68 & 3.7 & 2.28 & -0.35 (\pm 0.6, 0.57) \\ \mbox{Value} 2010 & 1.6 & 1.21 & 54 & 1.97 & 1.66 & 44 & 318 & -0.29 (\pm 0.60, 0.11) \\ \mbox{Value} 2013 & 1.68 & 1.21 & 54 & 1.97 & 1.66 & 44 & 318 & -0.29 (\pm 0.60, 0.11) \\ \mbox{Value} 2013 & 1.68 & 1.21 & 54 & 1.97 & 1.66 & 3.78 & 3.03 (\pm 0.66, 0.57) \\ \mbox{Value} 2016 (7) & 5.4 & 2.218 & 1.162 & 1.16 & 1.48 & 2.08 & 1.38 & 3.78 & -0.32 (\pm 0.48, 0.44) \\ \mbox{Value} 2016 (6) & 6.3 & 7.22 & 7.5 & 181 & 17.7 & 1.002 & 17.4 & 4.28 & 2.378 & -0.32 (\pm 0.48, 0.44) \\ \mbox{Value} 2016 (6) & 7.4 & 5.2 & 3.16 & 4.6 & 3.18 & 8.7 & 3.88 & -0.34 (\pm 0.24, 0.07) \\ $									
$ \begin{array}{c} \mbox{Faphih} 2015 & -6.7 & 6.8 & 6.7 & -6.7 & 6.5 & 6.7 & 3.5 \end{tabular}{lllllllllllllllllllllllllllllllllll$									
Yoon 2015 14.41 13.88 39 14.78 14.19 42 2.9% -0.32 [0.46, 0.41] Sun 2018 166.3 66.56 105 198.6 70.36 95 3.8% -0.34 [0.62, 0.02] Heterogenetic Tat <sup>1</sup> = 0.00, Chi <sup>1</sup> = 13.27, df=12 (P=0.35); l <sup>1</sup> = 10% Test for verall effect Z=1.55 (P=0.12); l <sup>2</sup> = 10% Test for verall effect Z=1.55 (P=0.12); l <sup>2</sup> = 10% Vin 2005 204 13.46 41 25.8 13.44 40 2.9% -0.37 [-1.16, 0.43] Ni v 2005 204 13.46 41 25.8 13.44 40 2.9% -0.37 [-1.16, 0.43] Ni v 2005 204 13.46 51 22 121 230 135.76 12 0.2% O'Mahomy 2005 (d) 4.6 2.55 26 5.09 2.8 25 2.2% -0.18 [-0.37, 0.17] O'Mahomy 2005 (d) 4.6 2.55 26 5.09 2.8 25 2.2% -0.18 [-0.37, 0.7] O'Mahomy 2005 (d) 4.6 2.55 26 5.09 2.8 25 2.2% -0.73 [-1.16, 0.43] O'Mahomy 2005 (d) 4.6 2.55 27 2.63 0.74 25 2.2% -0.78 [-1.36, 0.7] Simmén 2010 3.3 0.68 37 3.8 0.68 37 2.7% -0.73 [-1.12, 0.7] Somdergaard 2011 2.07 0.85 27 2.63 0.74 25 2.2% -0.38 [-0.30, 0.28] Hitchial 2013 1.56 1.21 54 1.97 1.85 44 3.1% -0.28 [-0.68, 0.11] Chardonnead 2013 1.56 1.21 54 1.97 1.85 44 2.2% -0.37 [-0.68, 0.02] Heterogenetic 2013 1.56 1.21 54 1.97 1.85 44 2.2% -0.37 [-0.68, 0.02] Heterogenetic 2013 1.56 1.21 54 1.97 1.85 44 2.2% -0.38 [-0.60, 0.25] Heterogenetic 2013 2.30 100 43 270 103 33 2.8% -0.37 [-0.60, 0.67] Heterogenetic 2013 1.56 1.21 54 1.97 1.85 44 2.17 2.8% -0.38 [-0.60, 0.60] Heterogenetic 2013 1.56 1.21 54 1.97 1.85 2.23 7.4% -0.38 [-0.60, 0.61] Heterogenetic 2013 1.56 1.21 54 1.97 1.85 2.23 2.4% -0.38 [-0.60, 0.61] Heterogenetic 2013 1.56 1.21 54 1.97 1.96 2.3 7% -0.38 [-0.60, 0.61] Heterogenetic 2013 1.56 1.21 54 1.97 1.96 2.3 7% -0.38 [-0.60, 0.61] Heterogenetic 2013 1.56 1.21 54 1.97 1.97 1.97 1.97 1.97 1.97 1.97 1.97									
Sun 2018 168.3 66.56 105 198.6 70.36 95 3.8% -0.34 ( $b.62$ , $-0.06$ ) Heterogeneiky: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 13.27, df = 12 ( $P = 0.36$ ); $P = 10\%$ Test for overall effect Z = 1.35 ( $P = 0.12$ ) <b>2.2.2 Intervention duration</b> = 36wk Kim 2003 103 46.5 12 121 46.9 13 1.5% -0.37 ( $f.1.6$ , 0.43 Kiajander 2005 204 13.46 41 26.8 13.4 40 2.9% -0.47 ( $f.0.81$ , 0.03 NW 2005 268 132.89 21 230 135.76 18 2.0% 0.28 ( $h.38$ , 0.41 O'Mahony 2005 ( $h.34$ , 6 2.55 2.6 5.09 2.8 25 2.2% -0.78 ( $h.38$ , 0.18 ( $h.38$ , 0.19 O'Mahony 2005 ( $h.34$ , 6 2.55 2.6 5.09 2.8 2.5 2.2% -0.78 ( $h.38$ , 0.19 O'Mahony 2005 ( $h.16$ , 73 43 01 80.11 48 24 2.2% -1.12 ( $h.13$ , 0.019 O'Mahony 2005 ( $h.16$ , 73 43 0.18 0.1 43 3.0% -0.34 ( $h.07$ , 0.019 O'Mahony 2005 ( $h.16$ , 73 43 0.18 0.1 43 3.0% -0.14 ( $h.03$ , 0.14 ( $h.33$ , 0.19 O'Mahony 2015 ( $h.16$ , 73 43 0.18 0.1 14.8 24 2.2% -1.12 ( $h.13$ , 0.019 O'Mahony 2016 ( $h.16$ , 73 43 0.18 0.1 13 3.0 8 9 1.4% -0.12 ( $h.04$ ), 0.041 Nimein 2011 3.0 68 37 2.7% -0.34 ( $h.02$ , 0.051 Charlot 11 12. 0.8 15 1.3 0.8 9 1.4% -0.12 ( $h.04$ , 0.040 ( $h.04$ ) Williams 2009 7.64 1.24 1.97 1.16 22 3.2% -0.33 ( $h.04$ , 0.041 O'Mahony 2013 1.56 1.21 54 1.37 1.08 23 2.2% -0.33 ( $h.04$ , 0.041 Charbonneau 2013 1.61 183 39 5.61 1.31 37 2.2% 0.35 ( $h.010$ , 0.081 Roberts 2013 2.30 199 43 2.70 103 3.2 2.8% -0.37 ( $h.03$ , 0.044 U <sub>1</sub> 2016 ( $h.1$ 13.7 7.2 ( $h.13$ , 2.1 ( $h.1$ 197 ( $h.16$ 2.1 ( $h.2$ 2.3% -0.37 ( $h.03$ , 0.044 U <sub>1</sub> 2016 ( $h.1$ 2.2 1.03 12.4 1.82 1.06 62 3.7% -0.39 ( $h.04$ , 0.044 U <sub>1</sub> 2016 ( $h.1$ 7.5 4.3 69 8.1 1.31 37 2.8% 0.35 ( $h.010$ , 0.30 Sistemenson 2014 199.13 1.17 74 4.00.01 131 4.4% 0.048 ( $h.16$ , 0.33 Sistemenson 2014 199.13 1.17 74 ( $h.2$ ( $h.2$ 0.0001); $P = 74\%$ Test for overall effect Z = 0.37 ( $h.1$ 2.1 ( $h.1$ 197 ( $h.10$ 197 4.2% Test for overall effect Z = 0.37 ( $h.1$ 2.4 ( $h.2$ 0.0001); $P = 53.8\%$ Test for overall effect Z = 0.37 ( $h.2$ 0.0000); $P = 74\%$ Test for overall effect Z = 0.07; $Ch^{2} = 9.70$ , $df = 3.4$ ( $h.2$ 0.0000); $P = 74\%$ Test for overall effect Z = 0.07; $Ch^{2} = 9.7$									
Subtoral (05% C)         CBS									
Heterogeneki, Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 13.27, df = 12 (P = 0.35); P = 10%. Testor overall effect Z = 1.55 (P = 0.12) 2.22 Intervention duration Stawk Kim 2005 103 44.85 12 121 46.9 13 1.5% -0.37 [-116, 0.43] Nir 2005 208 122.89 21 220 135.76 18 2.0% 0.28 0.38 0.01] O'Mahony 2005 (4) 4.8 2.55 2.6 5.09 2.8 25 2.4% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 2.4 5.09 2.8 25 2.2% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 2.4 5.09 2.8 25 2.2% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 2.4 5.09 2.8 25 2.2% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 2.4 5.09 2.8 2.5 2.2% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 2.4 5.09 2.8 2.5 2.2% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 2.4 5.09 2.8 2.5 2.2% -0.78 [-1.36, 0.19] O'Mahony 2005 (5) 2.89 2.5 1.3 0.89 14.4 2.2% -0.12 [-0.50, 0.10] Michai 2010 3.3 0.86 37 3.8 0.88 37 2.7% -0.73 [-1.30, 0.26] Hichai 2011 1.2 0.8 155 1.3 0.89 14.4 2.2% -0.33 [-0.00, 0.25] BegTup 2013 1.56 1.21 54 1.97 1.65 444 3.1% -0.29 [-0.66, 0.11] Chadomera 2013 6.16 1.81 3.3 9 6.61 1.31 7 2.2% -0.33 [-0.00, 0.05] Bestor 2014 2.2 1.03 124 1.82 1.06 62 3.7% 0.03 [-0.06, 0.04] Ura 2016 (6) 4.8 7.2 1.31 4.4 80.2 131 4.4% 0.08 [-0.16, 0.30] Spiller 2016 (6) 4.8 4 5.5 41 7.9 4.2 38 2.2% -0.16 [-0.51, 0.39] Spiller 2016 (6) 4.8 4 5.5 41 7.9 4.2 38 2.2% -0.16 [-0.51, 0.39] Spiller 2016 (7) 5.0.8 82.4 (1.29 44 80.2 131 4.4% 0.08 [-0.16, 0.30] Spiller 2016 (6) 4.8 4 5.5 41 7.9 4.2 38 2.2% 0.10 [-0.34, 0.54] Spiller 2016 (7) 5.0.8 82.4 (1.29 44 80.2 131 4.4% 0.08 [-0.16, 0.30] Spiller 2016 (8) 4.8 4 5.5 41 7.9 4.2 88 2.2% 0.10 [-0.34, 0.54] Spiller 2016 (7) 5.4 3 6.9 4.1 38 51 3.3% -0.23 [-0.30, 0.06] Heterogenekiy Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 9.70; df = 34.07 + 0.00001); P = 65% Test for avalleffect Z = 3.08 (P = 0.005) Test for avalleffect Z = 3.78 (P = 0.005) Test for overall effect Z = 3.79 (P = 0.04) (1) does of probidet (1 \times 10^6) (2) does of probidet (1 \times 10^6) (3) Biddotacterium (4) high dose (4) BS-C		100.3 0							•
Test for overall effect $Z = 1.55$ (P = 0.12) 2.2 Intervention duration >8wk Kim 2005 004 13.46 14 26.8 13.44 40 2.9% -0.37 [-1.16, 0.43] Kiander 2005 204 13.46 14 26.8 13.44 40 2.9% -0.37 [-1.16, 0.43] Niv 2005 (0) 4.6 2.55 26 5.09 2.8 25 2.4% -0.18 [+0.73, 0.37] O'Mahomy 2005 (6) 2.99 2.5 2.4 5.09 2.8 25 2.2% -0.78 [-1.36, 0.19] O'Mahomy 2005 (6) 2.99 2.5 2.4 5.09 2.8 25 2.2% -0.78 [-1.36, 0.19] Williams 2008 7.64 1.24 2.9 0.18 1.48 24 22.2% -0.78 [-1.36, 0.19] Williams 2008 7.64 1.24 2.9 0.18 1.48 24 2.2% -0.73 [-1.30, 0.19] Michai 2010 3.3 0.88 37 3.8 0.68 37 2.7% -0.73 [-1.30, 0.29] Michai 2011 1.2 0.8 15 1.3 0.48 14 24 2.2% -0.73 [-1.30, 0.29] Michai 2011 1.207 0.85 27 2.63 0.74 25 2.3% -0.38 [-0.08] [-1.5, 0.13] Chadoniz 1.56 1.21 54 1.97 1.65 44 3.3% -0.22 [-0.68 0.01] Chadoniz 2013 1.56 1.21 54 1.97 1.65 44 3.3% -0.22 [-0.68 0.01] Chadoniz 2013 1.56 1.21 54 1.97 1.65 44 3.3% -0.23 [-0.68 0.01] Chadoniz 2013 1.56 1.21 54 1.97 1.65 44 3.3% -0.35 [-0.08 0.167] Siesan 2014 2.2 103 124 1.82 1.06 22 3.7% -0.37 [-0.80, 0.67] Siesan 2014 2.2 103 124 1.82 1.06 22 3.7% -0.37 [-0.80, 0.67] Siesan 2014 2.2 1.03 124 1.82 1.06 22 3.7% -0.32 [-0.68 0.61] Lyna 2016 (f) 4.63 7.2.2 13 44 60.2 131 4.4% 0.05 [0.16, 0.30] Spliter 2016 (f) 7.5 4.2 3 86 0.61 3.8 51 2.3% -0.35 [-0.50, 0.00] Juna 2016 (f) 7.5 4.2 3 86 0.61 3.8 51 2.3% -0.35 [-0.50, 0.60] Siesan 2014 2.2 7.5 181 17.9.7 10.02.179 4.2.% -0.32 [-0.50, 0.00] Juna 2016 (f) 7.5 4.2 3 69 0.61 3.8 51 2.3% -0.35 [-0.50, 0.00] Juna 2016 (f) 7.5 4.2 36 0.61 3.8 51 2.3% -0.35 [-0.50, 0.00] Juna 2016 (f) 7.5 4.2 3 69 0.61 3.8 51 2.3% -0.35 [-0.50, 0.00] Juna 2016 (f) 7.5 4.2 4.2 0.07] Total (95% C) 1.2 75 181 17.9.7 10.02.179 4.2.% -0.32 [-0.50, 0.00] Total (95% C) 1.2 75 191 17.9.7 10.02.179 4.2.% -0.32 [-0.50, 0.00] Total (95% C) 1.2 75 191 17.9.7 10.02.179 4.2.% -0.32 [-0.50, 0.00] Total (95% C) 1.2 75 191 17.9.7 10.02.179 4.2.% -0.32 [-0.50, 0.00] Total (95% C) 1.2 75 191 17.9.7 10.02.179 4.2.% -0.32 [-0.50, 0.00] Total (95% C) 1.2 75 10		= 0.00; Chi <sup>2</sup> =					01.0%	-0.00 [-0.20, 0.02]	
$ \begin{array}{c} \mbox{ki} \mbox{loss} & 103 \ 48.5 \ 12 \ 121 \ 46.9 \ 13 \ 1.5\% \ -0.37 \ 1.16 \ 0.43 \ .0.47 \ 0.16 \ 0.31 \ .0.5\% \ .0.47 \ 0.16 \ 0.31 \ .0.5\% \ .0.47 \ 0.16 \ 0.31 \ .0.5\% \ .0.47 \ 0.18 \ 0.32 \ 0.36 \ 0.31 \ .0.5\% \ .0.47 \ 0.36 \ 0.31 \ .0.5\% \ .0.47 \ 0.36 \ 0.31 \ .0.5\% \ .0.47 \ 0.36 \ 0.31 \ .0.5\% \ .0.47 \ 0.36 \ .0.5\% \ .0.47 \ 0.36 \ .0.5\% \ .0.47 \ 0.36 \ .0.5\% \ .0.46 \ .0.5\% \ $				12 (1 = 0.0					
Kajander 2005       20.4       13.46       41       26.8       13.44       40       2.9% $-0.47 + 0.91 - 0.03$ Niv 2005       28       12.20       135.76       18       20% $0.28 + 0.36 + 0.31$ $0.91$ Vivianovy 2005 (4)       4.6       2.55       2.6       50.90       2.8       2.5       2.4% $-0.78 + 1.36 - 0.19$ Kajander 2008       7.44       1.24       2.8       9.10       1.48       2.12 + 1.71 - 0.31 $0.76 + 1.36 - 0.19$ Kajander 2005       7.64       1.24       2.8       9.11 + 1.48       2.12 + 1.71 - 0.31 $0.34 + 0.77$ - 0.021         Sondergaard 2011       2.1       0.8       27       2.63       -0.68 + 1.25 - 0.131         Cha 2012       1.5       0.3       2.4       1.77 - 0.8       2.2 2%       -0.33 + 0.90 - 0.261         Michael 2013       0.16 + 1.21 - 0.13 - 0.21 + 0.55 - 0.131       0.22 + 0.58 - 0.011       0.24 + 0.02 + 0.51 - 0.011         Charbonneau 2013       6.18 + 1.83       39 - 5.61 + 1.31 + 1.2 + 2.2 + 0.53 + 0.08 - 0.041       0.29 + 0.58 - 0.041       0.29 + 0.58 - 0.041         Stevenso 2014       1.93 + 1.24 + 1.04 + 0.2 + 0.31 + 0.04 + 0.42 + 0.024 + 0.42 + 0.031 + 0.42 + 0.031 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 + 0.041 +									
Ni 2005 0' Mahony 2005 (d) 46 255 265 092 103 104 104 104 104 104 104 104 104									
O'Nahony 2005 (6) 2.99 2.5 24 5.09 2.8 25 2.4% -0.18 $[0.73, 0.37]$ O'Nahony 2005 (5) 2.99 2.5 24 5.09 2.8 25 2.2% -0.78 $[-1.36, 0.19]$ Kajander 2008 7.64 1.24 28 9.18 1.48 24 2.2% -0.78 $[-1.36, 0.19]$ Simmén 2009 7.64 1.24 28 9.18 1.48 24 2.2% -1.12 $[1.7, 0.08]$ Williams 2009 7.64 1.24 28 9.18 1.48 24 2.2% -0.13 $[1.20, 0.26]$ Michal 2011 1.2 0.8 15 1.3 0.8 9 1.4% -0.12 $[0.95, 0.11]$ Cha 2012 1.5 0.3 24 1.7 0.8 23 2.2% -0.38 $[1.26, 0.13]$ Charbonneau 2013 6.18 1.83 39 5.61 1.31 37 2.8% 0.36 $[0.00, 0.61]$ Roberts 2013 2.30 109 43 2.70 103 33 2.8% -0.37 $[0.68, 0.06]$ Roberts 2013 2.30 109 43 2.70 103 33 2.8% -0.37 $[0.68, 0.06]$ Roberts 2013 2.10 104 4.3 2.70 103 33 2.8% -0.37 $[0.60, 0.67]$ Sitsen 2014 2.2 1.03 124 1.82 1.06 62 3.7% 0.28 $[0.00, 0.61]$ Roberts 2013 6.18 1.83 39 5.61 1.31 37 2.8% 0.36 $[0.10, 0.61]$ Roberts 2013 6.18 1.83 39 5.61 1.31 37 2.8% 0.36 $[0.00, 0.61]$ Roberts 2013 6.18 1.83 39 5.61 1.31 37 2.8% 0.36 $[0.00, 0.61]$ Roberts 2013 6.18 1.83 39 5.61 1.31 37 2.8% 0.36 $[0.00, 0.61]$ Roberts 2013 7.5 1.21 4.4 8.02 131 4.1% 0.06 $[0.16, 0.30]$ Uyra 2016 (6) 7.5 4.3 60 8.1 3.8 51 3.3% -0.15 $[0.50, 0.00]$ Spiller 2016 (6) 7.5 4.3 60 8.1 3.8 51 3.3% -0.15 $[0.50, 0.00]$ Spiller 2016 (7) 5.4 3.4 60 8.1 3.8 51 3.3% -0.16 $[0.51, 0.22]$ Ishaque 2018 11.52 75 181 179.7 1002 179 4.2% -0.73 $[0.94, 0.51]$ Subtotal (95% C) 1930 1796 100.% -0.18 $[-0.30, -0.06]$ Heterogenety. Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 34 ( $P < 0.00001$ ); P = 74% Test for overall effect Z = 2.79 (P = 0.005) Total (95% C) 1930 1796 100.% -0.18 $[-0.30, -0.06]$ Heterogenety. Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 34 ( $P < 0.00001$ ); P = 65% Test for roverall effect (1 × 10 <sup>9</sup> ) (2) doses of probiotic (1 × 10 <sup>9</sup> ) (3) Bifdobacterium (4) high dose (7) low dose (8) IBS-C (9) IBS-D									
$\begin{array}{c} O' Mahom' 2005 (6) & 2.99 & 2.5 & 2.4 & 5.09 & 2.8 & 2.5 & 2.28 & -0.78 [\pm 3.6] & -0.34 [\pm 0.77, 0.08] \\ Kajander 2009 & 2.4 & 16.73 & 4.3 & 30 & 18.01 & 4.3 & 30\% & -0.34 [\pm 0.77, 0.08] \\ Williams 2009 & 7.4 & 1.24 & 9.18 & 1.48 & 24 & 2.28 & -1.72 [\pm 0.95, 0.71] \\ Sondergaard 2011 & 3.3 & 0.68 & 37 & 3.8 & 0.68 & 37 & 2.78 & -0.73 [\pm 1.20, -0.26] \\ Michai 2011 & 1.2 & 0.8 & 15 & 1.3 & 0.8 & 9 & 1.48 & -0.24 [\pm 0.68, 0.11] \\ Sondergaard 2011 & 2.07 & 0.85 & 27 & 2.63 & 0.74 & 25 & 2.3\% & -0.03 [\pm 0.90, 0.25] \\ Begtrup 2013 & 1.56 & 1.21 & 54 & 1.97 & 1.65 & 44 & 3.1\% & -0.29 [\pm 0.68, 0.11] \\ Chabonneau 2013 & 6.18 & 1.83 & 39 & 5.61 & 1.31 & 37 & 2.8\% & 0.35 [\pm 0.10, 0.81] \\ Roberts 2013 & 2.01 & 109 & 43 & 270 & 103 & 33 & 2.8\% & -0.37 [\pm 0.38, 0.09] \\ Stevenson 2014 & 2.2 & 1.03 & 124 & 1.82 & 1.06 & 62 & 3.7\% & 0.38 [0.06, 6.07] \\ Stevenson 2014 & 1.92 & 1.19 & 44 & 80.2 & 131 & 4.1\% & 0.06 [\pm 0.16, 0.33] \\ Spiller 2016 (6) & 48.3 & 72.2 & 131 & 44 & 80.2 & 131 & 4.1\% & 0.06 [\pm 0.16, 0.33] \\ Spiller 2016 (6) & 7.3 & 4 & 82 & 8.6 & 4.8 & 98 & 3.7\% & -0.29 [\pm 0.59, 0.00] \\ Spiller 2016 (6) & 7.3 & 4 & 82 & 8.6 & 4.8 & 98 & 3.7\% & -0.29 [\pm 0.59, 0.00] \\ Spiller 2016 (6) & 7.3 & 4 & 82 & 8.6 & 4.8 & 98 & 3.7\% & -0.29 [\pm 0.59, 0.00] \\ Spiller 2016 (6) & 7.3 & 4 & 80.2 & 131 & 4.1\% & 0.06 [\pm 0.16, 0.33] \\ Spiller 2016 (6) & 7.5 & 4.3 & 69 & 8.1 & 3.8 & 51 & 3.3\% & -0.16 [\pm 0.30, -0.06] \\ Heterogeneity Tau" = 0.17, Chi" = 9.24, df = 21 (P < 0.00001); P = 74\% \\ Test for subgroup differences: Chi" = 2.17, df = 1 (P = 0.14), P = 53.8\% \\ \hline Total (95\% Cl) & 1930 & 1796 & 100.0\% & -0.18 [\pm 0.30, -0.06] \\ Heterogeneity Tau" = 0.07; Chi" = 97.07, df = 34 (P < 0.00001); P = 74\% \\ Test for subgroup differences: Chi" = 2.17, df = 1 (P = 0.14), P = 53.8\% \\ \hline Total (95\% Cl) & 10.30 & 10.454 \\ \hline (1) does of probiotic (1 \times 10^6) \\ (2) does of probiotic (1 \times 10^6) \\ (3) does of probiotic (1 \times 10^6) \\ (3) does of probiotic (1 \times 10^6) \\ (4) does divence interval interval in the terval interval interval interval interval inte$									
Williams 2009       7.64       1.24       28       9.18       1.48       24       2.2%       -1.12 [1.71], -1.0, -0.26]         Michail 2011       1.2       0.8       37       3.8       0.68       37       2.7%       -0.73 [-1.20, -0.26]         Michail 2011       1.2       0.8       1.4%       -0.12 [-0.96, 0.71]       -0.73 [-0.90, 0.25]         Cha 2012       1.5       0.3       24       1.7       0.8       2.2%       -0.03 [-0.90, 0.25]         Begtrup 2013       1.56       1.21       54       1.97       1.66       2.2%       -0.03 [-0.00, 0.51]         Charbonneau 2013       6.18       1.83       39       561       1.31       37       2.8%       0.35 [-0.10, 0.81]         Stevenson 2014       1.913       1.97       2.8%       0.36 [0.06, 0.07]									
Simoré 2010 3.3 0.68 37 3.8 0.68 37 2.7% -0.73[ $-12.0.26$ ] Michail 2011 1.2 0.8 15 1.3 0.8 9 1.4% -0.12[ $+0.95, 0.71$ ] Sondergaard 2011 2.07 0.85 27 2.63 0.74 25 2.3% -0.05[ $+1.25, -0.13$ ] Cha 2012 1.5 0.3 24 1.7 0.8 23 2.2% -0.33[ $-0.00, 0.25$ ] Begtrup 2013 1.56 1.21 54 1.97 1.65 4.4 31% -0.24[ $+0.68, 0.11$ ] Roberts 2013 2.30 109 43 2.70 103 33 2.8% -0.37[ $+0.83, 0.09$ ] Sisson 2014 2.2 1.03 124 1.82 1.06 62 3.7% 0.36[ $0.10, 0.61$ ] Roberts 2013 2.20 109 43 2.70 103 33 2.8% -0.37[ $+0.83, 0.09$ ] Sisson 2014 199.13 119.7 54 201.98 97.44 27 2.8% -0.36[ $0.10, 0.61$ ] Lyra 2016 (6) 4.83 7.2.2 131 44 80.2 131 4.1% 0.06 [ $-0.18, 0.44$ ] Lyra 2016 (7) 50.8 82.4 129 44 80.2 131 4.0% 0.08[ $0.16, 0.33$ ] Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% -0.29[ $+0.59, 0.00$ ] Lyra 2016 (7) 50.8 82.4 129 44 80.2 131 4.0% 0.08[ $0.16, 0.33$ ] Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% -0.29[ $+0.59, 0.00$ ] Lyra 2016 (7) 7.5 4.3 60 8.1 3.8 51 3.3% -0.15[ $+0.50, 0.00$ ] Subtrati (95% C1) 1245 1113 62.4% -0.24[ $+0.42, -0.07$ ] Heterogeneity, Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 ( $P < 0.00001$ ); $P = 65\%$ Test for overall effect Z = 2.70 ( $P = 0.002$ ) Total (95% C1) 1930 1796 100.0% -0.18[ $-0.30, -0.06$ ] Heterogeneity, Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 ( $P < 0.00001$ ); $P = 65\%$ Test for overall effect Z = 2.70 ( $P = 0.002$ ) Total (95% C1) 1930 1796 100.0% -0.18[ $-0.30, -0.06$ ] Heterogeneity, Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 ( $P < 0.00001$ ); $P = 65\%$ Test for overall effect Z = 2.70 ( $P = 0.002$ ) Total (95% C1) 1930 1796 100.0% -0.18[ $-0.30, -0.06$ ] Heterogeneity, Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 ( $P < 0.00001$ ); $P = 65\%$ Test for overall effect Z = 2.70 ( $P = 0.002$ ) Total (95% C1) 5000000 ( $1 \times 10^6$ ) (2) doses of probiotic ( $1 \times 10^6$ ) (3) doses of probiotic ( $1 \times 10^6$ ) (4) Lactobaclilus (5) Bifdobacterium (6) high dose (7) low dose (8) BS-C									
Michail 2011       1.2       0.8       1.3       0.8       9       1.4% $-0.12[-0.95, 0.71]$ Sondergaard 2011       2.07       0.85       27       2.63       0.74       25       2.3% $-0.09[-15, -0.13]$ Cha 2012       1.5       0.3       2.4       1.7       0.8       2.3% $-0.03[-0.90, 0.25]$ Begtrup 2013       1.56       1.21       54       1.97       1.66       44       3.1% $-0.29[-0.96, 0.11]$ Charboneau 2013       2.10       1.21       54       1.97       1.66       2.3% $0.035[-0.10, 0.05]$ Stevenson 2014       2.2       1.03       124       1.82       1.06       62       3.7% $0.03[-0.40, 0.41]$ Lyra 2016 (6)       48.3       7.2       130       0.24       0.046[-0.17]       0.30         Spliller 2016 (8)       8.4       5.5       41       7.9       4.2       38       3.3% $-0.24[-0.54, 0.54]$ Spliller 2016 (9)       8.4       5.5       41       7.9       4.2       38       3.3% $-0.24[-0.34, 0.54]$ Spliller 2016 (10)       15.2       7.5       181       17.9       4.2 % $-0.73[-0.94$									
Sondergaard 2011 2.07 0.85 27 2.63 0.74 25 2.3% $-0.69[+25,-013]$ Cha 2012 1.5 0.3 24 1.7 0.8 23 2.2% $-0.33[+0.90, 0.25]$ Begtrup 2013 1.56 1.21 54 1.97 1.65 4.4 3.1% $-0.29[+0.69, 0.11]$ Charbonneau 2013 6.18 1.83 39 5.61 1.31 37 2.8% $-0.37[+0.83, 0.08]$ Sisson 2014 2.2 1.03 124 1.82 1.06 62 3.7% $-0.37[+0.83, 0.06]$ Sisson 2014 1.99.13 119.7 54 201.98 97.44 27 2.8% $-0.03[+0.49, 0.44]$ Lyra 2016 (6) 48.3 7.2. 131 4.4 80.2 131 4.1% $0.06[+0.19, 0.30]$ Lyra 2016 (7) 50.8 82.4 129 44 80.2 131 4.1% $0.06[+0.19, 0.30]$ Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% $-0.29[+0.59, 0.00]$ Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% $-0.29[+0.59, 0.00]$ Spiller 2016 (9) 7.5 4.3 69 8.1 3.8 51 3.3% $-0.15[+0.51, 0.22]$ Ishaque 2018 115.2 7.5 181 17.97 10.2 179 4.2% $-0.73[+0.94, -0.51]$ Subtotal (95% CI) 1245 1113 62.4% $-0.24[+0.42, -0.07]$ Heterogeneity: Tau" = 0.07; Chi" = 97.07, df = 34 (P < 0.00001); P = 65%. Test for overall effect Z = 2.79 (P = 0.0002) Total (95% CI) 1930 1796 100.0% $-0.18[+0.30, -0.06]$ Heterogeneity: Tau" = 0.07; Chi" = 97.07, df = 34 (P < 0.00001); P = 53.8% Footnotes 10 does of problotic (1 × 10 <sup>0</sup> ) (2) doess of problotic (1 × 10 <sup>0</sup> ) (3) doess of problotic (1 × 10 <sup>0</sup> ) (4) Lactoballius (5) Bifdobacterium (6) high does (7) low dose (8) IBS-C									
Char2oT2 1.5 0.3 24 1.7 0.8 23 2.2% -0.33 [0.00, 0.25] Begtrup 2013 1.56 1.21 54 1.97 1.65 44 3.1% -0.29 [0.68, 0.11] Charbonneau 2013 1.56 1.21 54 1.97 1.65 44 3.1% -0.29 [0.68, 0.11] Roberts 2013 2.30 109 43 270 103 33 2.8% -0.37 [0.83, 0.09] Sisson 2014 2.2 1.03 124 1.82 1.06 6.2 3.7% -0.38 [0.06, 0.67] Stevenson 2014 199.13 119.7 54 201.98 97.44 27 2.8% -0.36 [0.46, 0.44] Lyra 2016 (6) 48.3 72.2 131 44 80.2 131 4.0% 0.08 [0.16, 0.3] Spiller 2016 (7) 5.0 8 82.4 129 44 80.2 131 4.0% 0.08 [0.16, 0.39, 0.00] Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% -0.29 [0.59, 0.00] Spiller 2016 (9) 7.5 4.3 69 8.1 3.8 51 3.3% -0.16 [0.34, 0.64] Spiller 2016 (1) 7.5 4.3 69 8.1 3.8 51 3.3% -0.16 [0.51, 0.22] Ishaque 2018 115.2 75 181 179.7 100.2 179 4.2% -0.73 [0.94, 0.61] Subtoal (95% C1) 1245 1113 62.4% -0.24 [-0.42, -0.07] Heterogeneity: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect $Z = 2.79$ (P = 0.000) Total (95% C1) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneity: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect $Z = 2.33$ (P = 0.002) Total (95% C1) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneity: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect $Z = 2.33$ (P = 0.002) Total (95% C1) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneity: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 4 (P < 0.14), P = 53.8% <u>Foolnotes</u> (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) Lat CobacIlius (5) Bildobacterium (6) high dose (7) low dose (8) BS-C									
Begrup 2013 1.56 1.21 54 1.97 1.65 44 3.1% $-0.29 [0.69, 0.11]$ Charbonneau 2013 6.18 1.83 39 5.61 1.31 37 2.8% $0.35 [0.10, 0.61]$ Roberts 2013 2.03 109 43 2.70 103 33 2.8% $0.35 [0.10, 0.61]$ Sitserson 2014 2.2 1.03 124 1.82 1.06 62 3.7% $0.36 [0.04, 0.67]$ Sitserson 2014 199.13 119.7 54 201.98 97.44 2.28% $-0.37 [0.68, 0.67]$ Sitserson 2014 199.13 119.7 54 201.98 97.44 2.28% $-0.03 [0.49, 0.44]$ Lyra 2016 (6) 48.3 72.2 131 44 80.2 131 4.1% $0.06 [0.19, 0.30]$ Lyra 2016 (7) 50.8 82.4 129 44 80.2 131 4.1% $0.08 [0.16, 0.3]$ Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% $-0.29 [0.59, 0.00]$ Spiller 2016 (8) 7.5 4.3 69 8.1 3.8 6.1 3.3% $-0.15 [0.54, 0.54]$ Spiller 2016 (10) 7.5 4.3 69 8.1 3.8 6.1 3.3% $-0.24 [0.42, -0.07]$ Heterogeneity, Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 74% Test for overall effect Z = 2.79 (P = 0.005) Total (95% CI) 1930 1796 100.0% $-0.18 [-0.30, -0.06]$ Heterogeneity, Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 53.8% Footnotes Footnotes (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) lactochrium (5) Bild dose (7) low dose (8) BS-C									
Roberts 2013       230       109       43       270       103       33       2.8% $-0.37(0.83, 0.09]$ Sisson 2014       2.2       1.03       124       1.82       1.06       62       3.7%       0.036(0.6, 0.67)         Stevenson 2014       1931       119.       74       218 $-0.37(0.83, 0.09)$ $0.44$ Lyra 2016 (6)       44.3       72.2       131       4.4       80.2       131       4.1%       0.06[0.67]         Spiller 2016 (6)       43.3       72.2       131       4.4       80.2       131       4.1%       0.06[0.33]         Spiller 2016 (7)       50.8       82.4       129       44       80.2       131       6.1%       0.034 (0.54)         Spiller 2016 (8)       7.3       4       82       8.6       4.8       98       3.7% $-0.29(0.34, 0.54)$ Spiller 2016 (10)       7.5       4.3       63       3.3% $-0.16[0.51, 0.23]$ Subtoal (95% C1)       11245       1113       62.4% $-0.24[0.42, -0.07]$ $-0.16[0.30, -0.06]$ Heterogeneity: Tau"= 0.07; Chi"= 97.07, df = 34 (P < 0.00001); IP = 65% $-0.18[0.30, -0.06]$ $-1$ $-0.5$ $0$ $0.5$									
Sisson 2014 2.2 1.03 124 1.82 1.06 62 3.7% 0.36 [0.06 0.67] Stevenson 2014 199.13 119.7 54 201.98 97.44 27 2.28% -0.03 [-0.49, 0.44] Lyra 2016 (6) 48.3 72.2 131 44.1% 0.06 [-0.19, 0.30] Lyra 2016 (7) 50.8 82.4 129 44 80.2 131 4.1% 0.08 [-0.16, 0.33] Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% -0.29 [-0.59, 0.00] Spiller 2016 (9) 8.4 5.5 41 7.9 4.2 38 2.9% 0.10 [-0.34, 0.54] Spiller 2016 (1) 7.5 4.3 69 8.1 3.8 51 3.3% -0.15 [-0.54], 0.22] Ishaque 2018 115.2 75 181 17.9. 10.2 179 4.2% -0.73 [-0.34, -0.51] Heterogeneiky: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 74% Test for overall effect Z = 3.03 (P = 0.002) Total (95% C1) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneiky: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect Z = 3.03 (P = 0.002) Total (95% C1) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneiky: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect Z = 3.03 (P = 0.002) Total (95% C1) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneiky: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 53.8% Footnotes (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) Lactoballus (5) Bildobacterium (6) high dose (7) low dose (8) IB3-C					1.31	37	2.8%		
Stevenson 2014 199.13 119.7 54 201.98 97.44 27 2.8% -0.03 $(-0.46)$ 0.44] Lyra 2016 (6) 48.3 72.2 131 44 80.2 131 4.1% 0.06 $[-0.16]$ 0.30] Spiller 2016 (6) 7.3 4 82 8.6 4.8 98 3.7% -0.29 $[-0.59, 0.00]$ Spiller 2016 (7) 5.0 8 82.4 129 44 80.2 131 4.0% 0.08 $[-0.16]$ 0.30] Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% -0.29 $[-0.59, 0.00]$ Spiller 2016 (9) 7.5 4.3 69 8.1 3.8 51 3.3% -0.16 $[-0.34]$ 0.54 Spiller 2018 (15.2 75 181 179.7 100.2 179 4.2% -0.73 $[-0.94, -0.51]$ Subtotal (95% C) 1245 1113 62.4% -0.24 $[-0.42, -0.07]$ Heterogeneity: Tau <sup>2</sup> = 0.17; Ch <sup>2</sup> = 80.24, df = 21 (P < 0.00001); P = 74% Test for overall effect Z = 2.79 (P = 0.002) Test for subgroup differences: Chi <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 53.8% Footnotes (1) doses of problotic (1 × 10 <sup>6</sup> ) (2) doses of problotic (1 × 10 <sup>6</sup> ) (2) doses of problotic (1 × 10 <sup>6</sup> ) (3) doses of problotic (1 × 10 <sup>6</sup> ) (4) Lactobachus (5) Bifdobacterium (6) Bidd hose (7) low dose (8) BS-C									
Lyra 2016 (6) 48.3 72.2 131 44 80.2 131 4.1% 0.06 [c.016, 0.30] Lyra 2016 (7) 50.8 82.4 129 44 80.2 131 4.1% 0.06 [c.016, 0.30] Spiller 2016 (8) 7.3 4 82 8.6 4.8 98 3.7% -0.29 [c.059, 0.00] Spiller 2016 (8) 7.4 3 69 8.1 3.8 51 3.3% -0.15 [c.051, 0.22] Ishaque 2018 115.2 75 181 179.7 100.2 179 4.2% -0.73 [c.04, -0.51] Subtotal (95% CI) 1245 1113 62.4% -0.24 [c.042, -0.07] Heterogeneity, Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 74% Test for overall effect Z = 2.79 (P = 0.005) Total (95% CI) 1930 1796 100.0% -0.18 [c.030, -0.06] Heterogeneity Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 55.8% Fost for verall effect Z = 30.3 (P = 0.002) Test for subgroup differences: Chi <sup>2</sup> = 2.17, df = 1 (P = 0.14), P = 53.8% Fost for verall effect Z = 0.07; Chi <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 55.8% Fost for verall effect Z = 0.07; Chi <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 53.8% Fost for verall effect Z = 0.07; Chi <sup>2</sup> = 97.07, df = 1 (P = 0.14), P = 53.8% Fost for verall effect Z = 0.005) Total (95% CI) 1930 1796 100.0% -0.18 [c.030, -0.06] Heterogeneity Tau <sup>2</sup> = 0.17; Chi <sup>2</sup> = 97.07, df = 1 (P = 0.14), P = 53.8% Fost for verall effect Z = 0.005) Total 05% of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) Lactobacellus (5) Bifdobacterium (6) Bigh dose (7) low dose (8) IBS-C									
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$									
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$									
Spiller 2016 (9)       8.4       5.5       4.1       7.9       4.2       38       2.9%       0.10 [0.34, 0.54]         Spiller 2016 (0)       7.5       4.3       69       8.1       3.8       51       3.3%       -0.15 [0.51, 0.22]         Ishaque 2018       115.2       75       181       179.7       100.2       179       4.2%       -0.73 [0.94, -0.51]         Subtotal (95% CI)       1245       1113       66.2%       -0.24 [-0.42, -0.07]         Heterogenelly: Tau" = 0.11; Chi" = 80.24, df = 21 (P < 0.00001); P = 74%									
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			5.5 4	7.9		38	2.9%	0.10 [-0.34, 0.54]	
Subtrait (95% CI)       1245       1113       62.4%       -0.24 [-0.42, -0.07]         Heterogeneity: Tau <sup>2</sup> = 0.11; CH <sup>2</sup> = 80.24, df = 21 (P < 0.00001); P = 74%								-0.15 [-0.51, 0.22]	
Heterogeneily: Tau <sup>2</sup> = 0.11; Ch <sup>2</sup> = 80.24, df = 21 (P < 0.00001); P = 74% Test for overall effect $Z = 2.79$ (P = 0.005) Total (95% Cl) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneily: Tau <sup>2</sup> = 0.07; Ch <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect $Z = 3.03$ (P = 0.002) Test for subgroup differences: Ch <sup>2</sup> = 2.17, df = 1 (P = 0.14), P = 53.8% Footnotes (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) Lactobactilius (5) Bildiobacterium (6) high dose (7) low dose (8) IBS-D		115.2							
Test for overall effect: $Z = 2.79$ (P = 0.005) Total (95% CI) 1930 1796 100.0% -0.18 [-0.30, -0.06] Heterogeneiky: Tau" = 0.07; Chi" = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect: Z = 3.03 (P = 0.002) Test for subgroup differences: Chi" = 2.17, df = 1 (P = 0.14), I" = 53.8% Footnotes (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) Lactobactilius (5) Bildobacterium (6) high dose (7) low dose (8) IBS-C		= 0.11: Chi <sup>2</sup> = 1					62.4%	-0.24 [-0.42, -0.07]	-
Heterogeneity, Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 97.07, df = 34 (P < 0.00001); P = 65% Test for overall effect: $Z = 3.03$ (P = 0.002) Test for subgroup differences: Chi <sup>2</sup> = 2.17, df = 1 (P = 0.14), P = 53.8% <u>Footnotes</u> (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>7</sup> ) (3) doses of probiotic (1 × 10 <sup>10</sup> ) (4) Lactboalcillus (5) Bifidobacterium (6) high dose (7) low dose (8) IBS-D									
Test for overall effect $Z = 3.03$ (P = 0.002) Test for subgroup differences: CDF = 2.17, df = 1 (P = 0.14), P = 53.8% Footnotes (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>10</sup> ) (4) Lactobac/Illus (5) Bifdobacterium (6) high dose (7) low dose (8) IBS-D							100.0%	-0.18 [-0.30, -0.06]	•
Test for subgroup differences: $Ch^2 = 2.03 (P = 0.002)$ Test for subgroup differences: $Ch^2 = 2.17$ , $df = 1 (P = 0.14)$ , $P = 53.8\%$ Footnotes (1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>6</sup> ) (3) doses of probiotic (1 × 10 <sup>6</sup> ) (4) Lactobacílius (5) Bifidobacterium (6) high dose (7) low dose (8) IBS-C				34 (P < 0.0	10001); l² =	65%		-	-1 -0.5 0 0.5 1
Footnotes           (1) doses of probiotic (1 × 10 <sup>6</sup> )           (2) doses of probiotic (1 × 10 <sup>8</sup> )           (3) doses of probiotic (1 × 10 <sup>10</sup> )           (4) Lactobacillus           (5) Bifidobacterium           (6) high dose           (7) low dose           (8) IBS-D				- 1 /P - 0 -	14) 12-50	0.06			
(1) doses of probiotic (1 × 10 <sup>6</sup> ) (2) doses of probiotic (1 × 10 <sup>7</sup> ) (3) doses of probiotic (1 × 10 <sup>17</sup> ) (4) Lactobacílius (5) Bifidobacterium (6) high dose (7) low dose (8) IBS-C (9) IBS-D		ierences. Uni	- 2.17, ui	- 1 (F = 0.	14/, 1 = 53	.0 70			
(2) doses of probiotic (1 × 10 <sup>8</sup> ) (3) doses of probiotic (1 × 10 <sup>10</sup> ) (4) Lactobacilius (5) Bildobacterium (6) Biddo dose (7) Iow dose (8) IBS-C (9) IBS-D		4 4 4 6							
(3) doses of problotic (1 × 10 <sup>170</sup> ) (4) Lactobacillus (5) Bilfdobacterium (6) high dose (7) low dose (8) IBS-C (9) IBS-D	(2) doses of probioti	$(1 \times 10^8)$							
(5) Blfddbacterium (6) high dose (7) Iow dose (8) IBS-C (9) IBS-D	(3) doses of probioti	c (1 × 10 <sup>10</sup> )							
(6) high dose (7) low dose (8) IBS-C (9) IBS-D	(4) Lactobacillus								
(7) low dose (8) IBS-C (9) IBS-D									
(8) IBS-C (9) IBS-D									
(9) IBS-D									
(10) IBS-M	(10) IBS-M								
	3 005 00000								



Farup et al., 2012; Charbonneau et al., 2013; Pedersen et al., 2014; Stevenson et al., 2014; Faghihi et al., 2015; Lyra et al., 2016; Spiller et al., 2016; Sun et al., 2018) using single probiotics were found a beneficial efficacy on global IBS symptoms scores (SMD -0.06; 95% CI -0.16 to 0.14; Figure 7), with low heterogeneity (I<sup>2</sup> = 33%, P = 0.12). In the subgroup of geographic position, we assigned 2 trials (Kim et al., 2003; Michail and Kenche, 2011) in USA to the North America group; seven comparisons of five separate papers (Whorwell et al., 2006; Agrawal et al., 2009; Williams et al., 2009; Roberts et al., 2013; Sisson et al., 2014) in UK, three comparisons of 1 papers (Spiller et al., 2016) in France, and three comparisons of two separate papers (O'Mahony et al., 2005; Charbonneau et al., 2013) in Ireland to the Western Europe group; two trials (Begtrup et al., 2013; Pedersen et al., 2014) in Denmark, two trials (Simren and Lindh, 2006; Simrén et al., 2010) in Sweden, one trials (Sondergaard et al., 2011) in Denmark and Sweden, four comparisons of three papers

(Kajander et al., 2005; Kajander et al., 2008; Lyra et al., 2016) in Finland, and one trials (Farup et al., 2012) in Norway to the Northern Europe group; one trials (Guglielmetti et al., 2011) in Germany to the Central Europe group; three trials (Choi et al., 2011; Cha et al., 2012; Yoon et al., 2015) in Korea and two trials (Zeng et al., 2008; Sun et al., 2018) in China to the East Asian group; one trials (Niv et al., 2005) in Israel and one trials (Faghihi et al., 2015) in Iran to the West Asian group; and one trials (Ishaque et al., 2018) in Bangladesh to the South Asian group; and one trials (Stevenson et al., 2014) in South Africa to the South Africa group. There was a statistically significant benefit in favor of probiotics in North America group (SMD -0.25; 95% CI -0.82 to 0.32; Figure 8), with no significant heterogeneity noted between the studies  $(I^2 = 0\%, P = 0.68)$ , East Asian group (SMD -0.24; 95% CI -0.43 to -0.05;  $I^2 = 0\%$ , P = 0.81), and South Asian group (SMD 0.06; 95% CI -0.24 to 0.36;  $I^2 = 0\%$ , P = 0.45).

Study or Subgroup 2.4.1 North America Kim 2003	Mean SD 103 48.5	<u>Total Mea</u> 12 12	1 46.9	13	1.5%	V, Random, 95% Cl -0.37 [-1.16, 0.43]	N, Random, 95% Cl
Michail 2011 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: .		15 1 27 1 (P = 0.68); I <sup>a</sup>		9 22	1.4% 2.9%	-0.12 [-0.95, 0.71] - <b>0.25 [-0.82, 0.32]</b>	
2.4.2 Western Europe O'Mahony 2005 (1) O'Mahony 2005 (2) Whorwell 2006 (3) Whorwell 2006 (4) Whorwell 2006 (4) Whorwell 2006 (4) Whorwell 2006 (4) Agrawal 2009 Charbonneau 2013 Roberts 2013 Sisson 2014 Spiller 2016 (7) Spiller	4.6 2.55 2.99 2.5 6.09 2.37 5.06 2.37 6.22 2.47 24 16.73 7.64 1.24 6.18 1.83 230 109 2.2 1.03 7.3 4 8.4 5.5 7.5 4.3 0.09; Chi <sup>2</sup> = 40.05, df	26 5.0 24 5.0 90 5.9 90 5.9 90 5.9 17 3 28 9.1 39 5.6 43 27 124 1.6 82 8 41 7 69 8 763 769 8 763	9         2.8           1         2.49           1         2.49           1         2.49           0         18.01           8         1.48           1         1.31           0         103           2         1.06           6         4.8           9         4.2           1         3.8	25 25 92 92 17 24 37 33 62 98 38 51 686	2.4% 2.2% 3.8% 3.8% 3.8% 2.8% 2.8% 3.7% 3.7% 3.7% 3.3% <b>39.2</b> %	$\begin{array}{c} -0.18 \left[ -0.73 , 0.37 \right] \\ -0.78 \left[ +1.36 , -0.19 \right] \\ 0.07 \left[ +0.22 , 0.36 \right] \\ -0.35 \left[ -0.64 , -0.06 \right] \\ 0.12 \left[ -0.17 , 0.42 \right] \\ -0.34 \left[ +1.01 , 0.34 \right] \\ -1.32 \left[ +1.7 \right] \\ -1.7 \left[ +1.7 \right] \\ -0.37 \left[ -0.83 , 0.09 \right] \\ 0.35 \left[ -0.00 , 0.67 \right] \\ -0.37 \left[ -0.38 , 0.09 \right] \\ 0.36 \left[ -0.06 , 0.67 \right] \\ -0.29 \left[ -0.58 , 0.00 \right] \\ -0.15 \left[ -0.35 , 0.05 \right] \\ -0.15 \left[ -0.35 , 0.05 \right] \end{array}$	
2.4.3 Northern Europe Kajander 2005 Simren 2006 Kajander 2008 Simrén 2010 Sondergaard 2011 Farup 2012 Begtrup 2013 Pedersen 2014 Lyra 2016 (c) Lyra 2016 (c) Lyra 2016 (c) Heterogeneity, Tau <sup>*</sup> = Test for overall effect.	20.4 13.46 279 129 24 16.73 3.3 0.68 2.07 0.85 175 137 1.56 1.21 2.9 1.1 48.3 72.2 50.8 82.4 0.06; Chi <sup>2</sup> = 22.36, df	37 3 27 2.6 9 20 54 1.9 41 2 131 4 129 4 541	5 118 0 18.01 8 0.68 3 0.74 5 124 7 1.65 8 1 4 80.2 4 80.2	40 29 43 37 25 7 44 40 131 131 527	2.9% 2.5% 3.0% 2.7% 2.3% 1.1% 3.1% 2.9% 4.1% 4.0% 28.6%	$\begin{array}{c} 0.47 \left[ 0.91 , -0.03 \right] \\ 0.27 \left[ 0.25 , 0.79 \right] \\ -0.34 \left[ 0.77 , 0.08 \right] \\ -0.73 \left[ 1.20 , 0.26 \right] \\ -0.69 \left[ 1.25 , -0.13 \right] \\ -0.22 \left[ -0.80 , 0.11 \right] \\ -0.29 \left[ -0.80 , 0.11 \right] \\ 0.06 \left[ 0.14 , 0.53 \right] \\ 0.06 \left[ 0.16 , 0.33 \right] \\ -0.19 \left[ -0.40 , 0.02 \right] \end{array}$	
2.4.4 Central Europe Guglielmetti 2011 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect.		60 22 60	7 114	62 62	3.4% 3.4%	-0.17 [-0.52, 0.19] -0.17 [-0.52, 0.19]	-
2.4.5 East Asian Zeng 2008 Choi 2011 Cha 2012 Yoon 2015 Sun 2018 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect.		14 5.2 34 17 24 1 39 14.7 105 189 216 4 (P = 0.81); I <sup>a</sup>	2 99.51 7 0.8 8 14.19 6 70.36	15 33 23 42 95 208	1.7% 2.7% 2.2% 2.9% 3.8% 13.4%	-0.12 [-0.85, 0.61] -0.21 [-0.69, 0.27] -0.33 [-0.90, 0.25] -0.03 [-0.46, 0.41] -0.34 [-0.62, -0.06] -0.24 [-0.43, -0.05]	
2.4.6 West Asia Niv 2005 Faghihi 2015 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect.		67 -6 88		18 67 85	2.0% 3.5% 5.5%	0.28 [-0.36, 0.91] 0.00 [-0.34, 0.34] 0.06 [-0.24, 0.36]	•
2.4.7 South Asia Ishaque 2018 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect: .		181	7 100.2	179 179	4.2% 4.2%	-0.73 [-0.94, -0.51] -0.73 [-0.94, -0.51]	•
2.4.8 South Africa Stevenson 2014 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect.		54 201.9 54	8 97.44	27 27	2.8% 2.8%	-0.03 [-0.49, 0.44] - <b>0.03 [-0.49, 0.44]</b>	-
Total (95% CI) Heterogeneity: Tau* = Test for overal effect: Test for subgroup diff Foolnotes (1) Lactobaciterium (3) doses of probiotic (4) doses of probiotic (5) doses of probiotic (5) doses of probiotic (6) IBS-C (7) IBS-C (8) IBS-M (9) high dose (10) low dose	Z = 3.03 (P = 0.002) erences: Chi <sup>2</sup> = 25.77 $(1 \times 10^6)$ $(1 \times 10^8)$			%	100.0%	-0.18 [-0.30, -0.06] -	-1 -0.5 0 0.5 1 Favours (experimental) Favours (control)

# Efficacy of Probiotics on Individual Symptom Scores

There were 38 trials (Nobaek et al., 2000; Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Kajander et al., 2008; Sinn et al., 2008; Zeng et al., 2008; Agrawal et al., 2009; Williams et al., 2009; Simrén et al., 2010; Choi et al., 2011; Guglielmetti et al., 2011; Michail and Kenche, 2011; Sondergaard et al., 2011; Cha et al., 2012; Amirimani et al., 2013; Begtrup et al., 2013; Charbonneau et al., 2013; Roberts et al., 2013; Abbas et al., 2014; Jafari et al., 2014; Shavakhi et al., 2014; Sisson et al., 2014; Yoon et al., 2014; Pineton de Chambrun et al., 2015; Yoon et al., 2015; Spiller et al., 2016; Lyra et al., 2016; Majeed et al., 2016; Ishaque et al., 2018; Khodadoostan et al., 2018; Kim et al., 2018; Sun et al., 2018) including 44 comparisons with 4,579 patients reporting efficacy of probiotics on abdominal pain. Probiotics had effect on improving abdominal pain (SMD -0.22; 95% CI -0.33 to -0.11; Figure S6), but significant heterogeneity existed ( $I^2 = 70\%$ , P < 0.001). However, in subgroup analysis of probiotics dose, 24 comparisons (Kim et al., 2003; Kim et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008; Zeng et al., 2008; Agrawal et al., 2009; Williams et al., 2009; Simrén et al., 2010; Choi et al., 2011; Michail and Kenche, 2011; Sondergaard et al., 2011; Cha et al., 2012; Amirimani et al., 2013; Begtrup et al., 2013; Roberts et al., 2013; Sisson et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Lyra et al., 2016; Kim et al., 2018) using high dose were found a significant benefit over placebo (SMD = -0.14; 95% CI -0.26 to -0.01; Figure S7), with low heterogeneity ( $I^2 = 39\%$ , P = 0.03). There was no significant asymmetry in funnel plot (Egger test, P = 0.235; Figure S8), indicating no proof of publication bias.

Twenty-nine trials (Nobaek et al., 2000; Kim et al., 2003; Kim et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Zeng et al., 2008; Agrawal et al., 2009; Williams et al., 2009; Simrén et al., 2010; Choi et al., 2011; Guglielmetti et al., 2011; Michail and Kenche, 2011; Cha et al., 2012; Amirimani et al., 2013; Begtrup et al., 2013; Charbonneau et al., 2013; Roberts et al., 2013; Sisson et al., 2014; Abbas et al., 2014; Jafari et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Majeed et al., 2016; Lyra et al., 2016; Spiller et al., 2016; Kim et al., 2018; Sun et al., 2018) reported continuous data for the effect of probiotics on bloating scores in 3,496 patients. Probiotics had effect on improving bloating (SMD -0.13; 95% CI -0.24 to -0.03; Figure S9) and heterogeneity was found ( $I^2 =$ 54%, P < 0.01). In the subgroup of probiotics duration, 19 comparisons (Nobaek et al., 2000; Kim et al., 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Zeng et al., 2008; Agrawal et al., 2009; Choi et al., 2011; Guglielmetti et al., 2011; Amirimani et al., 2013; Abbas et al., 2014; Jafari et al., 2014; Yoon et al., 2014; Yoon et al., 2015; Kim et al., 2018; Sun et al., 2018) using a short treatment duration (<8 weeks) were found a significant benefit over placebo (SMD -0.13; 95% CI -0.27 to -0.01). Low heterogeneity was detected ( $I^2 = 47\%$ , P = 0.01). There was a beneficial effect on bloating in 22


comparisons (Kim et al., 2003; Kim et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Zeng et al., 2008; Agrawal et al., 2009; Williams et al., 2009; Simrén et al., 2010; Choi et al., 2011; Michail and Kenche, 2011; Cha et al., 2012; Amirimani et al., 2013; Begtrup et al., 2013; Roberts et al., 2013; Sisson et al., 2014; Yoon et al., 2015; Lyra et al., 2016; Kim et al., 2018) using high dose (SMD -0.07; 95% CI -0.20 to -0.06; **Figure S10**).Low heterogeneity among trials was discovered ( $I^2 = 38\%$ , P = 0.04).The funnel plot suggested the existence of asymmetry (Egger test, P = 0.095; **Figure S11**), indicating possible publication bias.

# Safety of Probiotics in IBS

Forty studies (Gade and Thorn, 1989; Niedzielin et al., 2001; Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; Niv et al., 2005; O'Mahony et al., 2005; Kim et al., 2006; Whorwell et al., 2006; Guyonnet et al., 2007; Enck et al., 2008; Kajander et al., 2008; Sinn et al., 2008; Zeng et al., 2008; Enck et al., 2009; Hong et al., 2009; Simrén et al., 2010; Choi et al., 2011; Guglielmetti et al., 2011; Michail and Kenche, 2011; Cha et al., 2012; Dapoigny et al., 2012; Ducrotte et al., 2012; Kruis et al., 2012; Amirimani et al., 2013; Begtrup et al., 2013; Charbonneau et al., 2013; Abbas et al., 2014; Lorenzo-Zuniga et al., 2014; Sisson et al., 2014; Stevenson et al., 2014; Yoon et al., 2014; Pineton de Chambrun et al., 2015; Lyra et al., 2016; Majeed et al., 2016; Spiller et al., 2016; Hod et al., 2017; Ishaque et al., 2018; Preston et al., 2018; Sun et al., 2018) provided safety-related data, which was assessed by adverse events. Fourteen trials (Gade and Thorn, 1989; Niedzielin et al., 2001; Kim et al., 2003; Kajander et al., 2005; Kim et al., 2005; Kim et al., 2006; Sinn et al., 2008; Simrén et al., 2010; Michail and Kenche, 2011; Dapoigny et al., 2012; Lorenzo-Zuniga et al., 2014; Yoon et al., 2015; Hod et al., 2017; Ishaque et al., 2018) reported that there were no adverse events. Four trials (O'Mahony et al., 2005; Whorwell et al., 2006; Majeed et al., 2016; Spiller et al., 2016) reported adverse events of both arms. Difference was detected between probiotics and placebo (RR = 1.07; 95% CI 0.92–1.24; Figure 9), with low heterogeneity (I<sup>2</sup> = 0, P = 0.83). The funnel plot suggested no evidence of asymmetry (Egger test, P = 0.808; Figure S12). Probiotics seem to be safer than placebo in IBS patients.

# DISCUSSION

Alterations of the intestinal microbiome could be relevant to IBS. Symptoms in IBS often developed after an infection, which was known as post-infectious IBS (Marshall et al., 2006; Marshall et al., 2007). Gut bacterial overgrowth may cause symptoms of IBS indistinguishable (Lin, 2004). Studies suggest that compared with the healthy group the colonic microbiome changes in IBS (Durban et al., 2013; Jalanka-Tuovinen et al., 2014). Despite there were many drugs and treatments for IBS, probiotics have shown beneficial (Simrén et al., 2013; Mozaffari et al., 2014). Probiotics may regulate



immunity in IBS to protect the intestine (Major and Spiller, 2014). Probiotics also modify the gut microbiota, which improves some IBS symptoms, such as flatulence, bloating, and altered bowel habits (Jeffery et al., 2012; Tap et al., 2017).

# Summary of Main Results

Many pieces of evidence have suggested that probiotics may benefit IBS symptoms (Shavakhi et al., 2014; Stevenson et al., 2014; Yoon et al., 2014). However, the results of clinical trials have been conflicting. Our meta-analysis has indicated that probiotics may be beneficial and safe to improve symptoms of IBS compared with placebo. However, it was difficult to draw a precise conclusion as a result of the existence of significant heterogeneity and possible publication bias. We found that a shorter treatment duration (< 8 weeks) could reduce global IBS symptoms scores and bloating scores (Whorwell et al., 2006; Guyonnet et al., 2007; Drouault-Holowacz et al., 2008). As a chronic and recurrent disease (Sun et al., 2018), the improvement of IBS symptoms seems to be detected after a long time by taking probiotics continuously. However, according to current research shorter treatment duration seemed to be more beneficial. But due to many dropouts in the longer duration group, there may have an impact on research results, manifesting as greater improvement in the shorter duration group (Roberts et al., 2013). Although the use of single probiotics tended to have a beneficial effect on improving the bloating scores (Majeed et al., 2016; Spiller et al., 2016; Kim et al., 2018; Sun et al., 2018), it was unknown

which strain or species was more beneficial than others. Using a high dose of probiotics may reduce abdominal pain scores and bloating scores (Yoon et al., 2014; Yoon et al., 2015; Kim et al., 2018). However, Lyra et al. tested two different doses (10<sup>10</sup> CFU/D, and 10<sup>9</sup> CFU/D) of Lactobacillus acidophilus NCFM and reported that none of the outcomes showed a dose-response effect (Lyra et al., 2016). Small differences of dosage may contribute to no effect of dose. Probiotics could benefit overall IBS symptoms improvement in North America, West Europe, Northern Europe, and East Asian.We also found that probiotics could reduce global IBS symptoms scores in North America, East Asian, and South Asian. More pieces of evidence are needed. Probiotics seemed safe for patients with irritable bowel syndrome (O'Mahony et al., 2005; Whorwell et al., 2006; Majeed et al., 2016; Spiller et al., 2016), but more long-term trials are required to prove it.

# **Strengths and Weaknesses**

Our meta-analysis is the first to assemble the efficacy and safety of probiotics for IBS patients with all diagnostic criteria by subgroup analyses of probiotic type, dose, treatment duration, and geographic position. We conducted this metaanalysis and systematic review using a rigorous and reproducible methodology. Two reviewers assessed eligibility and extracted data independently. The random-effects model was used to minimize the possibility of overestimating treatment results. We also tried to contact researchers of possibly eligible trials to get data. These comprehensive approaches included more than 3,300 IBS patients receiving probiotics treatment. Finally, subgroup analyses of probiotics type, dose, treatment duration, and geographic position were performed to evaluate the efficacy of treatment.

Our study has certain limitations. Bias risk of many studies was unknown, and the analysis shows considerable evidence of heterogeneity between trials. However, considering only studies with low bias risk, the positive effects remained. The number of studies on subgroup analyses of probiotics type, doses, and treatment duration was limited. It was not enough to detect significant differences in the efficacy of probiotics. In some studies, significant placebo effects have been found which can affect the results.

# CONCLUSIONS

In summary, this meta-analysis has demonstrated moderate evidence for the use and safety of probiotics in IBS. A shorter treatment duration (< 8 weeks) and a single probiotic may be more beneficial. Probiotics seem to be safe for patients with irritable bowel syndrome. There is still a need for more clinical trials. Finally, probiotics may be a beneficial therapy for IBS patients.

# DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/ **Supplementary Material**.

# REFERENCES

- Abbas, Z., Yakoob, J., Jafri, W., and Ahmad, Z.ND Islam, M. (2014). Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. *Eur. J. Gastroenterol. Hepatol.* 26, 630–639. doi: 10.1097/MEG.00000000000094
- Agrawal, A., Houghton, L. A., Morris, J., Reilly, B., Guyonnet, D., Goupil F., N., et al. (2009). Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. *Aliment. Pharmacol. Ther.* 29, 104–114. doi: 10.1111/j.1365-2036.2008.03853.x
- Amirimani, B., Nikfam, S., Albaji, M., Vahedi, S., and Vahedi, H. (2013). Probiotic vs. Placebo in Irritable Bowel Syndrome: A Randomized Controlled Trial. *Middle East J. Dig. Dis.* 5, 98–102.
- Andresen, V., Montori, V. M., Keller, J., West, C. P., Layer, P., and Camilleri, M. (2008). Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Clin. Gastroenterol. Hepatol.* 6, 545–555. doi: 10.1016/ j.cgh.2007.12.015
- Begtrup, L. M., de Muckadell, O. B., Kjeldsen, J., Christensen, R. D., and Jarbol, D. E. (2013). Long-term treatment with probiotics in primary care patients with irritable bowel syndrome-a randomised, double-blind, placebo controlled trial. *Scand. J. Gastroenterol.* 48, 1127–1135. doi: 10.3109/00365521.2013.825314
- Bundeff, A. W., and Woodis, C. B. (2014). Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. *Ann. Pharmacother.* 48, 777– 784. doi: 10.1177/1060028014528151
- Cha, B. K., Jung, S. M., Choi, C. H., Song, In-do., Lee, H. W., Kim, H. J., et al. (2012). The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a

# **AUTHOR CONTRIBUTIONS**

LZ and BL conceived and designed this study. BL and LL searched and selected studies. HD and JG extracted essential information. BL and HS assessed the risk of bias. BL and HD performed statistical analyses. BL and HS interpreted the pooled results. BL, LL, and LZ drafted the manuscript. All authors approved the final manuscript.

# **FUNDING**

This research was supported by the Youth Foundation of 960th Hospital of the PLA with a unique identifier of 2017QN03.

# ACKNOWLEDGMENTS

We would like to express our appreciation to all authors listed in these all primary studies which were included in the current systematic review and meta-analysis.

# SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020. 00332/full#supplementary-material

randomized, double-blind, placebo-controlled trial. J. Clin. Gastroenterol. 46, 220–227. doi: 10.1097/MCG.0b013e31823712b1

- Chang, L., Chey, W. D., Drossman, D., Losch-Beridon, T., Wang, M., Lichtlen, P., et al. (2016). Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. *Aliment. Pharmacol. Ther.* 44, 1114–1122. doi: 10.1111/apt.13807
- Charbonneau, D., Gibb, R. D., and Quigley, E. M. M. (2013). Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. *Gut. Microbes* 4, 201–211. doi: 10.4161/gmic.24196
- Chey, W. D., Lembo, A., Macdougall, J. E., Lavins, B. J., Schneier, H., and Johnston, J. M. (2011). Efficacy and Safety of Once-Daily Linaclotide Administered Orally for 26 Weeks in Patients With IBS-C: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. *Gastroenterology* 140, S-135. doi: 10.1016/S0016-5085(11)60550-7
- Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., and Myung, S. J. (2011). A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol. 45, 679–683. doi: 10.1097/mcg.0b013e31 8204593e
- Cui, S., Hu, Y., Lunaud, B., Cardot, J. M., and A. (2012). Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. *Int. J. Clin. Exp. Med.* 5, 238–244. doi: 10.1155/2012/952452
- Dapoigny, M., Piche, T., Ducrotte, P., Lunaud, B., Cardot, J. M., and Bern, A. (2012). Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J. Gastroenterol. 18, 2067–2075. doi: 10.3748/wjg.v18.i17.2067
- Dersimonian, R., and Laird, N. (1986). Meta-analysis in clinical trials. Control Clin. Trials 7, 177-178. doi: 10.1016/0197-2456(86)90046-2

- Drossman, D. A., Camilleri, M., Mayer, E. A., and Whitehead, W.E. (2002). AGA technical review on irritable bowel syndrome. *Gastroenterology* 123, 2108– 2131. doi: 10.1053/gast.2002.37095
- Drouault-Holowacz, S., Bieuvelet, S., Burckel, A., Cazaubiel, M., Dray, X., and Marteau, P. (2008). A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. *Gastroen. Clin. Biol.* 32, 147–152. doi: 10.1016/j.gcb.2007.06.001
- Ducrotte, P., Sawant, P., and Jayanthi, V. (2012). Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. *World J. Gastroenterol.* 18, 4012–4018. doi: 10.3748/wjg.v18.i30.4012
- Dupont, H. L. (2014). Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. *Aliment. Pharmacol. Ther.* 39, 1033–1042. doi: 10.1111/apt.12728
- Durban, A., Abellan, J. J., Jimenez-Hernandez, N., Artacho, A., Garrigues, V., Ortiz, V., et al. (2013). Instability of the faecal microbiota in diarrhoeapredominant irritable bowel syndrome. *FEMS Microbiol. Ecol.* 86, 581–589. doi: 10.1111/1574-6941.12184
- Egger, M., Davey, S. G., Schneider, M., and Minder, C. (1997). Bias in metaanalysis detected by a simple, graphical test. *BMJ* 315, 629–634. doi: 10.1136/ bmj.315.7109.629
- Enck, P., Zimmermann, K., Menke, G., Muller-lissner, S., Martens, U., and Klosterhalfen, S. (2008). A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome - a randomized controlled trial with primary care physicians. *Neurogastroenterol. Motil.* 20, 1103–1109. doi: 10.1111/j.1365-2982.2008.01156.x
- Enck, P., Zimmermann, K., Menke, G., and Klosterhalfen, S. (2009). Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. *Z Gastroenterol.* 47, 209–214. doi: 10.1055/s-2008-1027702
- Faghihi, A. H., Agah, S., Masoudi, M., Ghafoori, S. M., and Eshraghi, A. (2015). Efficacy of Probiotic Escherichia coli Nissle 1917 in Patients with Irritable Bowel Syndrome: a Double Blind Placebo-controlled Randomized Trial. Acta Med. Indones 47, 201–208.
- Farup, P. G., Jacobsen, M., Ligaarden, S. C., and Rudi, K. (2012). Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. *Gastroenterol. Res. Pract.* 2012, 214102. doi: 10.1155/2012/214102
- Gade, J., and Thorn, P. (1989). Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. *Scand. J. Prim Health Care* 7, 23–26. doi: 10.3109/02813438909103666
- Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., and Mayer, E. A. (2000). The impact of irritable bowel syndrome on health-related quality of life. *Gastroenterology* 119, 654–660. doi: 10.1053/gast.2000.16484
- Guarner, F., Khan, A. G., Garich, J., Eliakim, R., Gangl, A., Thompson, A., et al (2012). World Gastroenterology Organisation Global Guidelines[J]. J Clin Gastroenterol. 46 (6), 468–481. doi: 10.1097/MCG.0b013e3182549092
- Guglielmetti, S., Mora, D., Gschwender, M., and Popp, K. (2011). Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. *Aliment. Pharmacol. Ther.* 33, 1123–1132. doi: 10.1111/j.1365-2036.2011.04633.x
- Guyonnet, D., Chassany, O., Ducrotte, P., Picard, C., Mouret, M., Mercier, C. -H., et al. (2007). Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, doubleblind, controlled trial. *Aliment. Pharmacol. Ther.* 26, 475–486. doi: 10.1111/ j.1365-2036.2007.03362.x
- Hayes, P. A., Fraher, M. H., and Quigley, E. M. (2014). Irritable bowel syndrome: the role of food in pathogenesis and management. *Gastroenterol. Hepatol.* 10, 164–174. doi: 10.1111/j.1751-2980.2009.00392.x
- Higgins, J. P. T., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. in The Cochrane Collaboration. Available online at: http://handbook.cochrane.org.
- Higgins, J. P. T., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring inconsistency in meta-analyses. *BMJ* 327, 557–560. doi: 10.1136/ bmj.327.7414.557
- Hod, K., Sperber, A. D., Ron, Y., Boaz, M., Dickman, R., Berliner, S., et al. (2017). A double-blind, placebo-controlled study to assess the effect of a probiotic

mixture on symptoms and inflammatory markers in women with diarrheapredominant IBS. *Neurogastroenterol. Motil.* 29, e13037. doi: 10.1111/ nmo.13037

- Hong, K. S., Kang, H. W., Im, J. P., Ji, G. E., Kim, S. G., Jung, H. C., et al. (2009). Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. *Gut. Liver* 3, 101–107. doi: 10.5009/gnl.2009.3.2.101
- Hyland, N. P., Quigley, E. M., and Brint, E. (2014). Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J. Gastroenterol. 20, 8859–8866. doi: 10.3748/ wjg.v20.i27.8859
- Ishaque, S. M., Khosruzzaman, S. M., Ahmed, D. S., and Sah, M. P. (2018). A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. *BMC Gastroenterol.* 18, 71. doi: 10.1186/s12876-018-0788-9
- Jafari, E., Vahedi, H., Merat, S., and Riahi, A. (2014). Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. *Arch. Iran Med.* 17, 466–470. doi: 0141707/AIM.003
- Jalanka-Tuovinen, J., Salojarvi, J., Salonen, A., Immonen, O., Garsed, A., Kelly, F. M., et al. (2014). Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. *Gut* 63, 1737–1745. doi: 10.1136/gutjnl-2013-305994
- Jeffery, I. B., O'Toole, P. W., Ohman, L., Claesson, M. J., Deane, J., Quigley, EMM, et al. (2012). An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut* 61, 997–1006. doi: 10.1136/gutjnl-2011-301501
- Kajander, K., Hatakka, K., Poussa, T., and Färkkilä, M. A. (2005). A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. *Aliment. Pharmacol. Ther.* 22, 387–394. doi: 10.1111/ j.1365-2036.2005.02579.x
- Kajander, K., Myllyluoma, E., Rajilic-Stojanovic, M., Kyrönpalo, S., Rasmussen, M., Järvenpää, S., et al. (2008). Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. *Aliment. Pharmacol. Ther.* 27, 48–57. doi: 10.1111/j.1365-2036.2007.03542.x
- Khodadoostan, M., Shavakhi, A., Sherafat, Z., and Shavakhi, A. (2018). Effect of Probiotic Administration Immediately and 1 Month after Colonoscopy in Diarrhea-predominant Irritable Bowel Syndrome Patients. *Adv. BioMed. Res.* 7, 94. doi: 10.4103/abr.abr\_216\_17
- Kim, H. J., Camilleri, M., McKinzie, S., Lempke, M. B., Burton, D. D., Thomforde, G. M., et al. (2003). A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. *Aliment. Pharmacol. Ther.* 17, 895–904. doi: 10.1046/j.1365-2036.2003.01543.x
- Kim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., et al. (2005). A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. *Neurogastroenterol. Motil.* 17, 687–696. doi: 10.1111/j.1365-2982.2005.00695.x
- Kim, Y. G., Moon, J. T., Lee, K. M., Chon, N. R., and Park, H. (2006). The effects of probiotics on symptoms of irritable bowel syndrome. *Korean J. Gastroenterol.* 47, 413–419. doi: 10.4166/kjg.2009.54.6.413
- Kim, J. Y., Park, Y. J., Lee, H. J., Park, M. Y., and Kwon, O. (2018). Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial. *Food Sci. Biotechnol.* 27, 853–857. doi: 10.1007/s10068-017-0296-7
- Kruis, W., Chrubasik, S., Boehm, S., Stange, C., and Schulze, J. (2012). A doubleblind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. *Int. J. Colorectal Dis.* 27, 467–474. doi: 10.1007/s00384-011-1363-9
- Lin, H. C. (2004). Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292, 852–858. doi: 10.1001/ jama.292.7.852
- Lorenzo-Zuniga, V., Llop, E., Suarez, C., Alvarez, B., Abreu, L., Espadaler, J., et al. (2014). I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. *World J. Gastroenterol.* 20, 8709–8716. doi: 10.3748/wjg.v20.i26.8709
- Lovell, R. M., and Ford, A. C. (2012). Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. *Clin. Gastroenterol. Hepatol.* 10, 712–721.e4. doi: 10.1016/j.cgh.2012.02.029

- Ludidi, S., Jonkers, D. M., Koning, C. J., Kruimel, J. W., Mulder, L., Vaart, I. B., et al. (2014). Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. *Neurogastroenterol. Motil.* 26, 705–714. doi: 10.1111/nmo.12320
- Lyra, A., Hillilä, M., Huttunen, T., Männikkö, S., Taalikka, M., Tennilä, J., et al. (2016). Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. *World J. Gastroenterol.* 22, 10631–10642. doi: 10.3748/ wjg.v22.i48.10631
- Majeed, M., Nagabhushanam, K., Natarajan, S., Arumugam, S., Ali, F., Pande, F., et al. (2016). Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. *Nutr. J.* 15, 21. doi: 10.1186/s12937-016-0140-6
- Major, G., and Spiller, R. (2014). Irritable bowel syndrome, inflammatory bowel disease and the microbiome. *Curr. Opin. Endocrinol. Diabetes Obes.* 21, 15–21. doi: 10.1097/MED.00000000000032
- Marshall, J. K., Thabane, M., Garg, A. X., Clark, W.F., Salvadori, M., and Collins, S. M. (2006). Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. *Gastroenterology* 131, 445–450. doi: 10.1016/S0399-8320(07)89359-6
- Marshall, J. K., Thabane, M., Borgaonkar, M. R., and James, C. (2007). Postinfectious Irritable Bowel Syndrome After a Food-Borne Outbreak of Acute Gastroenteritis Attributed to a Viral Pathogen. *Clin. Gastroenterol. Hepatol.* 5, 457–460. doi: 10.1016/j.cgh.2006.11.025
- Mezzasalma, V., Manfrini, E., Ferri, E., Sandionigi, A., Ferla, B. L., Schiano, I., et al. (2016). A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. *BioMed. Res. Int.* 2016, 1–10. doi: 10.1155/2016/4740907
- Michail, S., and Kenche, H. (2011). Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome. *Probiotics Antimicrob.* 3, 1–7. doi: 10.1007/s12602-010-9059-y
- Mozaffari, S., Nikfar, S., and Abdollahi, M. (2014). The safety of novel drugs used to treat irritable bowel syndrome. *Expert Opin. Drug Saf.* 13, 625–638. doi: 10.1517/14740338.2014.902932
- Niedzielin, K., Kordecki, H., and Birkenfeld, B. (2001). A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. *Eur. J. Gastroenterol. Hepatol.* 13, 1143–1147. doi: 10.1097/00042737-200110000-00004
- Niv, E., Naftali, T., Hallak, R., and Vaisman, N. (2005). The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. *Clin. Nutr.* 24, 925–931. doi: 10.1016/j.clnu.2005.06.001
- Nobaek, S., Johansson, M. L., Molin, G., Ahrné, S., and Jeppsson, B. (2000). Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 95, 1231–1238. doi: 10.1016/S0002-9270(00)00807-8
- O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., et al. (2005). Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology* 128, 541– 551. doi: 10.1053/j.gastro.2004.11.050
- Parkes, G. C., Brostoff, J., Whelan, K., and Sanderson, J. D. (2008). Gastrointestinal Microbiota in Irritable Bowel Syndrome: Their Role in Its Pathogenesis and Treatment. Am. J. Gastroenterol. 103, 1557–1567. doi: 10.1111/j.1572-0241.2008.01869.x
- Pedersen, N., Andersen, N. N., Végh, Z., Jensen, L., Ankersen, D. V., Felding, M., et al. (2014). Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J. Gastroenterol. 20, 16215–16226. doi: 10.3748/wjg.v20.i43.16215
- Pineton de Chambrun, G., Neut, C., Chau, A., Cazaubiel, M., Pelerin, F., Justen, P., et al. (2015). A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. *Dig. Liver Dis.* 47, 119–124. doi: 10.1016/j.dld.2014.11.007
- Preston, K., Krumian, R., Hattner, J., de Montigny, D., Stewart, M., and Gaddam, S. (2018). Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a

double-blind, randomised, placebo-controlled study. *Benef. Microbes* 9, 697–706. doi: 10.3920/BM2017.0105

- Rahimi, R., Nikfar, S., Rezaie, A., and Abdollahi, M. (2009). Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J. Gastroenterol. 15, 1548–1553. doi: 10.3748/wjg.15.1548
- Roberts, L. M., McCahon, D., Holder, R., Wilson, S., and Hobbs, F. D. (2013). A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. *BMC Gastroenterol.* 13, 45. doi: 10.1186/1471-230X-13-45
- Shavakhi, A., Minakari, M., Farzamnia, S., Peykar, M. S., Taghipour, G., Tayebi, A., et al. (2014). The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: a randomized placebo-controlled trial. *Adv. BioMed. Res.* 3, 140. doi: 10.4103/2277-9175.135157
- Shin, S. P., Choi, Y. M., Kim, W. H., Hong, S. P., Park, J. M., Kim, J., et al. (2018). A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrheadominant irritable bowel syndrome. J. Clin. Biochem. Nutr. 62, 179–186. doi: 10.3164/jcbn.17-73
- Simrén, M., Ohman, L., Olsson, J., Svensson, U., Ohlson, K., Posserud, I., et al. (2010). Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, doubleblind, controlled study. *Aliment. Pharmacol. Ther.* 31, 218–227. doi: 10.1111/ j.1365-2036.2009.04183.x
- Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M., Spiller, R. C., and Vanner, S. (2013). Intestinal microbiota in functional bowel disorders: a Rome foundation report. *Gut* 62, 159–176. doi: 10.1136/gutjnl-2012-302167
- Simren, M. S. A., and Lindh, A. (2006). Effects of Lactobacillus plantarum 299V on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS)
  a randomized double blind controlled trial. *Gastroenterology* 130, A600. doi: 10.1016/S0016-5085(06)60008-5
- Sinn, D. H., Song, J. H., Kim, H. J., Lee, J. H., Son, H. J., Chang, D. K., et al. (2008). Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. *Digest. Dis. Sci.* 53, 2714–2718. doi: 10.1007/ s10620-007-0196-4
- Sisson, G., Ayis, S., Sherwood, R. A., and Bjarnason, I. (2014). Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndromea 12 week double-blind study. *Aliment. Pharmacol. Ther.* 40, 51–62. doi: 10.1111/apt.12787
- Sondergaard, B., Olsson, J., Ohlson, K., Svensson, U., Bytzer, P., and Ekesbo, R. (2011). Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebocontrolled trial. *Scand. J. Gastroenterol.* 46, 663–672. doi: 10.3109/ 00365521.2011.565066
- Spiller, R., Pelerin, F., Cayzeele Decherf, A., Maudet, C., Housez, B., Cazaubiel, M., et al. (2016). Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United Eur. Gastroenterol. J. 4, 353–362. doi: 10.1177/ 2050640615602571
- Stevenson, C., Blaauw, R., Fredericks, E., Visser, J., and Roux, S. (2014). Randomized clinical trial: Effect of lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. *Nutrition* 30, 1151–1157. doi: 10.1016/j.nut.2014.02.010
- Sun, Y. Y., Li, M., Li, Y. Y., Li, L. X., Zhai, W. Z., Wang, P., et al. (2018). The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrheadominant irritable bowel syndrome: a randomized, double-blind, placebocontrolled trial. *Sci. Rep.* 8, 2964. doi: 10.1038/s41598-018-21241-z
- Tack, J., Vanuytsel, T., and Corsetti, M. (2016). Modern Management of Irritable Bowel Syndrome: More Than Motility. *Dig. Dis.* 34, 566–573. doi: 10.1159/ 000445265
- Tap, J., Derrien, M., Tornblom, H., Brazeilles, R., Cools-Portier, S, Dore, J., et al. (2017). Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. *Gastroenterology* 152, 111–123. doi: 10.1053/j.gastro.2016.09.049.90. e8.
- Thijssen, A. Y., Clemens, C. H., Vankerckhoven, V., Goossens, H., Jonkers, D. M., and Masclee, A. A. (2016). Efficacy of Lactobacillus casei Shirota for patients

with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 28, 8-14. doi: 10.1097/MEG.0000000000484

- Trinkley, K. E., and Nahata, M. C. (2014). Medication management of irritable bowel syndrome. *Digestion* 89, 253–267. doi: 10.1159/000362405
- Wang, Y., Hwee, L., Tai, D., Krishnamoorthy, T. L., Tan, T., Barbier, S., et al. (2012). The impact of Irritable Bowel Syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 12, 104. doi: 10.1186/1471-230x-12-104
- Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., et al. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. *Am. J. Gastroenterol.* 101, 1581–1590. doi: 10.1111/j.1572-0241.2006.00734.x
- Williams, E. A., Stimpson, J., Wang, D., Plummer, S., Garaiova, I., Barker, M. E., et al. (2009). Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebocontrolled study. *Aliment. Pharmacol. Ther.* 29, 97–103. doi: 10.1111/j.1365-2036.2008.03848.x
- Yoon, J. S., Sohn, W., Lee, O. Y., Lee, S. P., Lee, K. N., and Jun, D. W. (2014). Effect of multispecies probiotics on irritable bowel syndrome: a randomized, doubleblind, placebo-controlled trial. *J. Gastroenterol. Hepatol.* 29, 52–59. doi: 10.1111/jgh.12322

- Yoon, H., Park, Y. S., Lee, D. H., Seo, J. G., Shin, C. M., and Kim, N. (2015). Effect of administering a multi-species probitic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, doubleblind, placebo-controlled trial. J. Clin. Biochem. Nutr. 57, 129–134. doi: 10.3164/jcbn.15-14
- Zeng, J., Li, Y. Q., Zuo, X. L., Zhen, Y.-B., Yang, J., and Liu, C.-H. (2008). Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. *Aliment. Pharmacol. Ther.* 28, 994–1002. doi: 10.1111/j.1365-2036.2008.03818.x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Liang, Deng, Guo, Shu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.